[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 13685
1. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB: Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol; 2010 Jun;5(6):1010-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
  • BACKGROUND AND OBJECTIVES: Hepcidin, the principal regulator of iron homeostasis, may play a critical role in the response of patients with anemia to iron and erythropoiesis-stimulating agent therapy; however, the contribution of hepcidin to iron maldistribution and anemia in hemodialysis (HD) patients and the ability of HD to lower serum hepcidin levels have not been fully characterized.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured serum hepcidin using a competitive ELISA in 30 pediatric and 33 adult HD patients.
  • In addition, we determined serum hepcidin kinetics and calculated hepcidin clearance by measuring serum hepcidin before, during, and after HD in eight pediatric and six adult patients.
  • RESULTS: Hepcidin was significantly increased in pediatric (median 240.5 ng/ml) and adult HD patients (690.2 ng/ml) when compared with their respective control subjects (pediatric 25.3 ng/ml, adult 72.9 ng/ml).
  • Multivariate regression analysis showed that serum hepcidin was independently predicted by ferritin and high-sensitivity C-reactive protein in the pediatric group and ferritin, percentage of iron saturation, and high-sensitivity C-reactive protein in the adult group.
  • Hepcidin clearance by HD was 141 +/- 40 and 128 +/- 44 ml/min in pediatric and adult patients, respectively (NS).
  • CONCLUSIONS: These findings suggest that hepcidin may mediate the negative effects of inflammation on both disordered iron metabolism and erythropoiesis in HD patients and that intensification of HD could be used therapeutically to reduce hepcidin concentrations and thereby improve erythropoiesis-stimulating agent responsiveness.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2002 Oct;110(7):1037-44 [12370282.001]
  • [Cites] Nephrol Dial Transplant. 2010 Mar;25(3):848-53 [19854845.001]
  • [Cites] Am J Kidney Dis. 2003 Nov;42(5):1020-35 [14582046.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1271-6 [15124018.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] Clin Nephrol. 2005 Mar;63(3):202-8 [15786821.001]
  • [Cites] Blood. 2005 May 15;105(10):4103-5 [15671438.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1864-6 [15886319.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1381-7 [16621968.001]
  • [Cites] Physiol Res. 2006;55(6):667-74 [16497104.001]
  • [Cites] Am J Nephrol. 2008;28(1):115-21 [17943020.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4292-7 [18689548.001]
  • [Cites] Kidney Int. 2009 May;75(9):976-81 [19212416.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Jun;4(6):1051-6 [19406957.001]
  • [Cites] Eur J Clin Invest. 2009 Oct;39(10):883-90 [19563467.001]
  • [Cites] J Proteomics. 2010 Jan 3;73(3):527-36 [19683083.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2461-3 [12433676.001]
  • (PMID = 20299375.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 5R01DK067563-04; United States / NIDDK NIH HHS / DK / R01 DK067563; United States / NIDDK NIH HHS / DK / R01 DK065029; United States / NIDDK NIH HHS / DK / 1K08DK074284-01; United States / NIDDK NIH HHS / DK / K08 DK074284
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Biomarkers; 0 / HAMP protein, human; 0 / Hematinics; 0 / Hepcidins; 0 / Inflammation Mediators; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  • [Other-IDs] NLM/ PMC2879302
  •  go-up   go-down


2. Bortvedt SF, McLear JA, Messer A, Ahern-Rindell AJ, Wolfgang WJ: Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease. Neurobiol Dis; 2010 Oct;40(1):130-4
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.
  • Huntington's disease (HD) is a lethal, neurodegenerative disorder caused by expansion of the polyglutamine repeat in the Huntingtin gene (HTT), leading to mutant protein misfolding, aggregation, and neuronal death.
  • Feeding a Drosophila HD model cystamine, or expressing a transgene encoding the anti-htt intracellular antibody (intrabody) C4-scFv in the nervous system, demonstrated therapeutic potential, but suppression of pathology was incomplete.
  • We hypothesized that a combinatorial approach entailing drug and intrabody administration could enhance rescue of HD pathology in flies and that timing of treatment would affect outcomes.
  • Feeding cystamine to adult HD flies expressing the intrabody resulted in a significant, additional rescue of photoreceptor neurodegeneration, but no additional benefit in longevity.
  • Feeding cystamine during both larval and adult stages produced the converse result: longevity was significantly improved, but increased photoreceptor survival was not.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • [Cites] Curr Opin Mol Ther. 2006 Feb;8(1):17-23 [16506521.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4246-51 [16537516.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1837-40 [10710314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9 [11296304.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):739-43 [11607033.001]
  • [Cites] Neurosci Lett. 2001 Nov 27;315(3):149-53 [11716985.001]
  • [Cites] Nat Med. 2002 Feb;8(2):143-9 [11821898.001]
  • [Cites] J Neurosci. 2002 Oct 15;22(20):8942-50 [12388601.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3825-30 [12458211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5950-5 [12730384.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R187-93 [12925571.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S10-7 [15272267.001]
  • [Cites] J Neurochem. 2004 Oct;91(2):413-22 [15447674.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Mol Cell Biochem. 1984;58(1-2):9-35 [6143256.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7388-93 [10377424.001]
  • [Cites] J Neurochem. 2005 Jan;92(1):83-92 [15606898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3777-81 [15716359.001]
  • [Cites] Eur J Neurosci. 2005 Feb;21(4):855-70 [15787692.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56 [15837560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5820-5 [15811941.001]
  • [Cites] Mol Ther. 2005 Sep;12(3):394-401 [15964243.001]
  • [Cites] J Neurochem. 2005 Oct;95(1):210-20 [16181425.001]
  • [Cites] Biochim Biophys Acta. 2006 Mar;1762(3):373-80 [16364609.001]
  • [Cites] Mov Disord. 2006 Apr;21(4):530-3 [16258942.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1410-24 [16604191.001]
  • [Cites] Neuroscience. 2006 Sep 15;141(4):1835-48 [16809003.001]
  • [Cites] Neuron. 2006 Oct 5;52(1):169-78 [17015234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11563-8 [16061794.001]
  • [Cites] Hum Mol Genet. 2008 Jan 15;17(2):170-8 [17921520.001]
  • [Cites] FASEB J. 2008 Jun;22(6):2003-11 [18199697.001]
  • [Cites] J Cell Biol. 2008 Jun 2;181(5):803-16 [18504298.001]
  • [Cites] FEBS J. 2008 Sep;275(17):4252-62 [18637947.001]
  • [Cites] J Neurochem. 2009 Jun;109(5):1427-39 [19476553.001]
  • [Cites] Expert Opin Biol Ther. 2009 Sep;9(9):1189-97 [19653865.001]
  • [Cites] J Neurosci. 2009 Oct 28;29(43):13589-602 [19864571.001]
  • [Cites] Nat Struct Mol Biol. 2009 Dec;16(12):1279-85 [19915590.001]
  • [Cites] J Cell Biol. 2009 Dec 28;187(7):1083-99 [20026656.001]
  • [Cites] Neuron. 2009 Dec 24;64(6):828-40 [20064390.001]
  • [Cites] J Mol Biol. 2010 Mar 12;396(5):1295-309 [20026071.001]
  • (PMID = 20399860.001).
  • [ISSN] 1095-953X
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS053912; United States / NINDS NIH HHS / NS / NS053912
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; R110LV8L02 / Cystamine
  • [Other-IDs] NLM/ NIHMS199601; NLM/ PMC2924926
  •  go-up   go-down


3. Chavers BM, Solid CA, Gilbertson DT, Collins AJ: Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J Am Soc Nephrol; 2007 Mar;18(3):952-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States.
  • Infection-related hospitalization (IH) incidence among US Medicare incident pediatric and adult dialysis and transplant patients within 3 yr of presentation was compared from 1996 to 2001: Hemodialysis (HD) patients (pediatric n = 1469; adult n = 305,323); peritoneal dialysis (PD) patients (pediatric n=982; adult n=27,119), and kidney transplant (KTx) patients (pediatric n=1108; adult n=31,663).
  • Cumulative incidence of IH at 36 mo for incident pediatric patients with ESRD during 1996 to 2001 was 39.9% in HD, 51.2% in PD, and 47.4% in KTx patients (HD or PD versus KTx, P<0.0001).
  • Cumulative incidence for adults was 52.6% in HD, 51.8% in PD, and 39.8% in KTx patients (HD or PD versus KTx, P<0.0001).
  • IH rates per 1000 patient-months were highest for pediatric KTx patients (adjusted rate ratio 1.53 versus HD and 1.90 versus PD, P<0.001 for each) and adult HD patients (adjusted rate ratio 1.20 versus KTx and 1.11 versus PD, P < 0.001 for each).
  • Within the first 36 mo of incidence, IH rates are highest for incident pediatric KTx patients compared with HD and PD patients, in contrast to findings for adult patients with ESRD.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17251389.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / N01-DK-9-2343
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A: Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A; 2005 Aug 9;102(32):11563-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
  • Misfolded neuronal proteins have been identified in a number of neurodegenerative disorders and have been implicated in the pathogenesis of diseases that include Alzheimer's disease, Parkinson's disease, prion-based dementia, Huntington's disease (HD), and other polyglutamine diseases.
  • Although underlying mechanisms remain the subject of ongoing research, it is clear that aberrant processing, protein degradation, and aggregate formation or spurious protein association of the abnormal neuronal proteins may be critical factors in disease progression.
  • We have modified an approach with intracellularly expressed single-chain Fv (sFv) antibodies (intrabodies) that bind with unique HD protein epitopes.
  • In cell and tissue culture models of HD, anti-N-terminal huntingtin intrabodies (C4 sFv) reduce aggregation and cellular toxicity.
  • Here, we present the crucial experiment of intrabody-mediated in vivo suppression of neuropathology, using a Drosophila model of HD.
  • In the presence of the C4 sFv intrabody, the proportion of HD flies surviving to adulthood increases from 23% to 100%, and the mean and maximum lifespan of adult HD flies is significantly prolonged.
  • [MeSH-major] Huntington Disease / pathology. Huntington Disease / therapy. Immunoglobulin Fragments / therapeutic use. Immunotherapy / methods. Lymphokines / immunology. Protein Engineering / methods. Sialoglycoproteins / immunology

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2001 Jan;3(1):113-21 [11162318.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):101-6 [11081516.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):739-43 [11607033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1002-7 [11792860.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):367-76 [11925563.001]
  • [Cites] Trends Genet. 2002 Apr;18(4):202-9 [11932021.001]
  • [Cites] Trends Genet. 2002 Sep;18(9):463-71 [12175807.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):855-64 [12372281.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41032-7 [12171927.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):373-9 [12540902.001]
  • [Cites] Nat Biotechnol. 2003 Feb;21(2):163-70 [12536217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2041-6 [12576549.001]
  • [Cites] Nat Rev Genet. 2003 Mar;4(3):181-94 [12610523.001]
  • [Cites] Science. 2003 Apr 18;300(5618):486-9 [12702875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5950-5 [12730384.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1253-9 [12761040.001]
  • [Cites] Mol Ther. 2003 Sep;8(3):355-66 [12946308.001]
  • [Cites] Annu Rev Neurosci. 2003;26:627-56 [12704223.001]
  • [Cites] Neuron. 2003 Sep 25;40(1):25-40 [14527431.001]
  • [Cites] Neuron. 2003 Nov 13;40(4):685-94 [14622574.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):141-5 [14969746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3224-9 [14978262.001]
  • [Cites] Biochemistry. 2004 Mar 16;43(10):2871-8 [15005622.001]
  • [Cites] Nat Rev Neurosci. 2004 May;5(5):373-84 [15100720.001]
  • [Cites] Bioessays. 2004 May;26(5):485-96 [15112229.001]
  • [Cites] FASEB J. 2004 May;18(7):923-5 [15001566.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):585-95 [15146184.001]
  • [Cites] Hum Mol Genet. 2004 Jul 1;13(13):1389-405 [15115766.001]
  • [Cites] Curr Mol Med. 2004 Aug;4(5):519-28 [15267223.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S2-9 [15272266.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S10-7 [15272267.001]
  • [Cites] J Mol Biol. 2004 Sep 17;342(3):901-12 [15342245.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Development. 1993 Jun;118(2):401-15 [8223268.001]
  • [Cites] Cell. 1996 Nov 1;87(3):493-506 [8898202.001]
  • [Cites] Adv Protein Chem. 1996;49:329-450 [8908302.001]
  • [Cites] Cell. 1997 Aug 8;90(3):537-48 [9267033.001]
  • [Cites] Science. 1997 Sep 26;277(5334):1990-3 [9302293.001]
  • [Cites] Neuron. 1998 Sep;21(3):633-42 [9768849.001]
  • [Cites] J Neurosci. 1999 Apr 1;19(7):2522-34 [10087066.001]
  • [Cites] J Exp Biol. 1999 Nov;202(Pt 21):3037-48 [10518485.001]
  • [Cites] Curr Opin Mol Ther. 2004 Oct;6(5):482-90 [15537049.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1023-31 [15564134.001]
  • [Cites] Hum Gene Ther. 2004 Nov;15(11):1131-54 [15610613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17616-21 [15598740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3777-81 [15716359.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56 [15837560.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):425-8 [10581028.001]
  • [Cites] Hum Mol Genet. 2000 Jan 1;9(1):13-25 [10587574.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1837-40 [10710314.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3081-7 [10955787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9 [11296304.001]
  • (PMID = 16061794.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Fv protein, human; 0 / HTT protein, human; 0 / Immunoglobulin Fragments; 0 / Lymphokines; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Sialoglycoproteins
  • [Other-IDs] NLM/ PMC1183604
  •  go-up   go-down


5. Cheema BS, Singh MA: Exercise training in patients receiving maintenance hemodialysis: a systematic review of clinical trials. Am J Nephrol; 2005 Jul-Aug;25(4):352-64
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exercise is not routinely advocated in patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis (HD), compared to best practice in other chronically diseased cohorts.
  • Lack of widespread awareness of the exercise in HD literature may be contributing to these shortcomings of clinical practice.
  • (1) to systematically review trials of exercise training involving adult HD patients;.
  • RESULTS: According to the 29 trials reviewed, HD patients can safely derive a myriad of health-related adaptations from engaging in appropriately structured exercise regimens involving aerobic and/or resistance training.
  • [MeSH-minor] Adaptation, Physiological. Adult. Clinical Trials as Topic. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16088076.001).
  • [ISSN] 0250-8095
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 48
  •  go-up   go-down


6. Borlongan CV, Thanos CG, Skinner SJM, Geaney M, Emerich DF: Transplants of Encapsulated Rat Choroid Plexus Cells Exert Neuroprotection in a Rodent Model of Huntington's Disease. Cell Transplant; 2007 Nov;16(10):987-992
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplants of Encapsulated Rat Choroid Plexus Cells Exert Neuroprotection in a Rodent Model of Huntington's Disease.
  • In the present study, CP was isolated from adult rats, encapsulated within alginate microcapsules, and transplanted unilaterally into the rat striatum.
  • Three days later, unilateral injections of quinolinic acid (QA; 225 nmol) were made into the ipsilateral striatum to mimic the pathology observed in Huntington's disease (HD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28866919.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Alginate / Choroid plexus / Encapsulation / Huntington's disease / Transplant
  •  go-up   go-down


7. Geevasinga N, Richards FH, Jones KJ, Ryan MM: Juvenile Huntington disease. J Paediatr Child Health; 2006 Sep;42(9):552-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile Huntington disease.
  • Huntington disease (HD) is a dominantly inherited neurodegenerative disorder related to expansion of a triplet repeat sequence in the huntington gene on chromosome 4.
  • Adult HD usually presents with chorea and personality changes.
  • Juvenile HD is far less common and presents with parkinsonism, dystonia and seizures.
  • We report a case of juvenile HD, showing extreme anticipation, in which diagnosis was delayed because of failure to recognise the significance of the family history and the characteristic clinical and radiologic features of this condition.
  • [MeSH-major] Diagnostic Errors. Huntington Disease / diagnosis
  • [MeSH-minor] Age of Onset. Child. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Polymorphism, Genetic


8. Ding SQ, Chen YT, Ding YJ, Liu F, Ye H: [Diagnosis and surgical management of adult Hirschsprung disease]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan;9(1):53-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical management of adult Hirschsprung disease].
  • OBJECTIVE: To investigate the diagnosis and surgical treatment of adult Hirschsprung disease (AHD).
  • CONCLUSIONS: The diagnosis of adult HD mainly depends on the history of constipation, barium enema and manometry examination.
  • The pull-through procedures are effective surgical treatments for adult HD.
  • [MeSH-major] Hirschsprung Disease / diagnosis. Hirschsprung Disease / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437373.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Tang Y, Wang Y, Yang P, Liu Y, Wang B, Podolsky R, McIndoe R, Wang CY: Intergeneration CAG expansion and contraction in a Chinese HD family. Am J Med Genet B Neuropsychiatr Genet; 2006 Apr 5;141B(3):242-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intergeneration CAG expansion and contraction in a Chinese HD family.
  • The prevalence of juvenile-onset Huntington's disease (HD) is about ten times lower than adult HD.
  • Here we report a Chinese HD family showing both intergeneration CAG expansion and contraction.
  • The expansion resulted from a paternal transmission which leads to juvenile-onset HD for a 17-year-old Chinese boy (III-5).
  • More interestingly, a contraction was noticed in a maternal transmission (III-3), which changed the CAG repeat from an expanded, disease-causing allele (48 repeats) to a normal or intermediate allele (34 repeats).
  • Our results are consistent with previous observations in Western Caucasians that juvenile-onset HD is more likely inherited through the male germline.
  • [MeSH-major] Huntington Disease / genetics. Nerve Tissue Proteins / genetics. Nuclear Proteins / genetics. Trinucleotide Repeat Expansion / genetics. Trinucleotide Repeats / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. China. Family Health. Female. Genotype. Humans. Inheritance Patterns. Male. Middle Aged. Pedigree. Polymorphism, Single Nucleotide. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16526033.001).
  • [ISSN] 1552-4841
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 143100
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


10. Schwartz CL: Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl; 2005 Jul;(66):55-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Special issues in pediatric Hodgkin's disease.
  • Childhood Hodgkin's disease (HD) is not a biologically unique disease; it differs from adult HD primarily in the relative incidence of disease histology.
  • Preadolescent children are more likely to have Mixed Cellularity and nodular lymphocyte predominant HD.
  • Adolescent and young adult HD is indistinguishable, with a predominance of nodular sclerosing (NS) HD.
  • The latter concerns are of equal relevance to the young adult with HD.
  • Although the dose dense regimens of adult groups are similar, the pediatric algorithms emphasize using the enhanced efficacy to limit cumulative therapy.
  • This review intends to address the special issues of childhood HD, with the intent of further encouraging understanding that will foster convergence of pediatric and adult treatment paradigms.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Child, Preschool. Combined Modality Therapy / adverse effects. Combined Modality Therapy / standards. Humans. Infant. Infant, Newborn. Radiotherapy / adverse effects. Radiotherapy / standards

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007870.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 80
  •  go-up   go-down


11. Kim HJ, Kim AY, Lee CW, Yu CS, Kim JS, Kim PN, Lee MG, Ha HK: Hirschsprung disease and hypoganglionosis in adults: radiologic findings and differentiation. Radiology; 2008 May;247(2):428-34
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hirschsprung disease and hypoganglionosis in adults: radiologic findings and differentiation.
  • PURPOSE: To retrospectively evaluate the imaging features of adult Hirschsprung disease (HD) and adult hypoganglionosis (HG) and to compare these features with histopathologic findings.
  • The imaging, medical, and histopathologic data of 10 patients (seven women, three men; mean age, 38 years) with histopathologically proved adult HD and/or adult HG were reviewed.
  • The CT findings of HD and HG were compared by using the Mann-Whitney U test.
  • The transition zone ratio was significantly different between the patients with HD (median ratio, 4.0) and the patients with HG (median ratio, 2.0) (P = .016).
  • However, there was no significant difference in the longitudinal length of the transition zone between the two patient groups (median ratios, 4.4 cm for HD group and 6.0 cm for HG group; P = .190).
  • CONCLUSION: A markedly dilated proximal colonic segment with a transition zone and a narrowed distal colonic segment on CT and double-contrast barium enema images in conjunction with chronic refractory constipation in an adult should suggest the diagnosis of adult HD or adult HG.
  • The detection of a much higher transition zone ratio may help to establish the diagnosis of HD.
  • [MeSH-major] Colon / innervation. Colon / radiography. Hirschsprung Disease / radiography
  • [MeSH-minor] Adult. Barium Sulfate. Contrast Media. Diagnosis, Differential. Enema. Female. Ganglia, Autonomic / pathology. Humans. Iohexol / analogs & derivatives. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18430875.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


12. Chen F, Winston JH 3rd, Jain SK, Frankel WL: Hirschsprung's disease in a young adult: report of a case and review of the literature. Ann Diagn Pathol; 2006 Dec;10(6):347-51
Genetic Alliance. consumer health - Hirschsprung's disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hirschsprung's disease in a young adult: report of a case and review of the literature.
  • Hirschsprung's disease (HD) in adults is rare and often undiagnosed or misdiagnosed.
  • We report a case of HD in a 26-year-old woman who had a history of chronic constipation that required laxatives and enemas since early childhood.
  • A rectal biopsy showed hypoganglionic anorectum, suspicious for HD.
  • A diagnosis of adult HD was made.
  • Hirschsprung's disease should be considered in adults who have long-standing and refractory constipation.
  • [MeSH-major] Hirschsprung Disease / pathology
  • [MeSH-minor] Adult. Chronic Disease. Constipation / complications. Constipation / pathology. Female. Humans. Proctocolectomy, Restorative. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126253.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Nguyen HP, Metzger S, Holzmann C, Koczan D, Thiesen HJ, von Hörsten S, Riess O, Bonin M: Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics Clin Appl; 2008 Dec;2(12):1638-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease.
  • Polyglutamine-induced changes in gene expression have been demonstrated by using several mouse models of Huntington's disease (HD), which express extreme numbers of CAG repeats.
  • We have recently developed a transgenic rat model of HD carrying a truncated huntingtin fragment with 51 CAG repeats, which is in the range seen in adult HD patients.
  • A detailed analysis of canonical pathways revealed that at 3 months of age genes in calcium signaling and synaptic long term potentation pathways were altered, while at 12 months of age, additionally, expression level of many genes implicated in Huntington's disease signaling, were changed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21136814.001).
  • [ISSN] 1862-8346
  • [Journal-full-title] Proteomics. Clinical applications
  • [ISO-abbreviation] Proteomics Clin Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Klepin HD, Song EY, Geiger AM, Tooze JA, Foley KL: Influence of age on receipt of chemotherapy for adult Medicaid beneficiaries with metastatic colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of age on receipt of chemotherapy for adult Medicaid beneficiaries with metastatic colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963615.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Powell SF, Dudek AZ: Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma.
  • : e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma.
  • METHODS: A retrospective analysis was performed all adult patients with Stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at our institution.
  • HD IL-2 was given I.V. every eight hours as a bolus over 15 minutes at a dose of 600,000 IU/kg.
  • RESULTS: A total of 15 patients with metastatic melanoma had been treated with HD IL-2 at our institution.
  • Complete response (CR) was seen in 6.67% (N=1), partial response (PR) in 6.67% (N=1), mixed response (MR) in 6.67% (N=1), and stable disease (SD) in 13.33% (N=2).
  • Average time to disease progression (TTDP) was 5.67 months in those with a PR or SD.
  • Two patients with brain metastases had subsequently complete resolution of the brain lesions after HD IL-2 therapy.
  • One of these patients has a CR and is disease free 34 months out from therapy.
  • The other had PR and is currently alive with disease, but has no recurrence of the brain lesion after over 19 months.
  • On average patients tolerated 10.5 HD IL-2 doses with the first course and 8.8 doses with the second course.
  • HD IL-2 has typically been avoided in patients with brain metastases due to concern for neurologic complications from the capillary leak syndrome caused by treatment.
  • We propose further evaluation of this ineligibility for HD IL-2, since carefully selected patients with brain metastases may derive benefit from this treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kober L, Rustom R, Wiedmann J, Kappelgaard AM, El Nahas M, Feldt-Rasmussen B: Cardiovascular effects of growth hormone in adult hemodialysis patients: results from a randomized controlled trial. Nephron Clin Pract; 2010;115(3):c213-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular effects of growth hormone in adult hemodialysis patients: results from a randomized controlled trial.
  • BACKGROUND/AIMS: The high morbidity and mortality rates in hemodialysis (HD) patients are due, at least in part, to their increased risk for cardiovascular diseases (CVD).
  • This prospective study evaluated the effect of growth hormone (GH) on a number of CVD risk markers in adult patients on HD.
  • METHODS: 139 HD patients were randomized to one of three GH doses or to placebo.
  • CONCLUSION: In adult HD patients, GH treatment had a predominantly beneficial effect on CVD risk markers.
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Female. Homocysteine / blood. Humans. Male. Middle Aged. Prospective Studies. Risk Factors. Serum Albumin / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20413999.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin; 0LVT1QZ0BA / Homocysteine; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


17. Bilgic A, Ozdemir FN, Bayraktar N, Karakus S, Sasak G, Arat Z, Sezer S, Haberal M: Soluble endothelial protein C receptor: influence on arteriovenous fistula thrombosis development in hemodialysis patients. Am J Nephrol; 2007;27(4):366-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Arteriovenous fistulae (AVF) thrombosis is a common cause of morbidity in hemodialysis (HD) patients.
  • We aimed to investigate the possible effects of sEPCR levels on the development of AVF thrombosis in adult HD patients.
  • METHODS: 60 HD patients and 22 healthy controls were included.
  • RESULTS: Mean plasma sEPCR levels were significantly higher in HD patients than they were in controls.
  • CONCLUSION: This is the first study to analyze sEPCR levels in HD patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Kidney Failure, Chronic / blood. Kidney Failure, Chronic / therapy. Male. Middle Aged. Renal Dialysis

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17570903.001).
  • [ISSN] 1421-9670
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / PROCR protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


18. Marsenic O, Zhang L, Zuppa A, Barrett JS, Pfister M: Application of Individualized Bayesian Urea Kinetic Modeling to pediatric hemodialysis. ASAIO J; 2010 May-Jun;56(3):246-53
Hazardous Substances Data Bank. UREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incorporating urea rebound using equilibrated urea concentration (Ceq) after hemodialysis (HD) is essential for accurate assessment of HD efficiency.
  • The objective of this work is to assess the ability of an Individualized Bayesian Urea Kinetic Model (IBKM) for predicting Ceq in children receiving HD.
  • Developed based on adult HD data, the IBKM is a two-pool urea kinetic model that calculates Bayesian estimates of individual Ceq.
  • Blood urea nitrogen (BUN) samples from 30 HD sessions in 13 children (age 12-18 years) were taken at pre-HD, immediately post-HD, and 60 minutes post-HD (Ceq).
  • The IBKM and estimated population parameters from adult data were fitted to the observed data from children to predict individual Ceq using NONMEM VI software in comparison with observed Ceq (9.5 +/- 3.8 mmol/L), the average individual predicted Ceq was 9.4 +/- 3.8 mmol/L, with absolute individual prediction error of 6.2% +/- 4.4%.
  • This study suggests that the IBKM can be used in a pediatric HD setting and accurately predict Ceq in children using only pre-HD and immediately post-HD BUN.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168209.001).
  • [ISSN] 1538-943X
  • [Journal-full-title] ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • [ISO-abbreviation] ASAIO J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8W8T17847W / Urea
  •  go-up   go-down


19. Kuo HL, Chou CY, Liu YL, Yang YF, Huang CC, Lin HH: Reduction of pro-inflammatory cytokines through hemodiafiltration. Ren Fail; 2008;30(8):796-800
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemodialysis (HD) prolongs the life of the patients with end stage renal disease (ESRD), but the survival rates are still lower than the general population.
  • More than half of ESRD patients died from cardiovascular disease (CVD).
  • METHODS: Seventeen adult HD outpatients were put on HDF in our hospital from September 2004 to June 2006.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791954.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-18; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


20. Higashi M, Ieiri S, Teshiba R, Saeki I, Esumi G, Taguchi T: Hirschsprung's disease patients diagnosed at over 15 years of age: an analysis of a Japanese nationwide survey. Pediatr Surg Int; 2009 Nov;25(11):945-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hirschsprung's disease patients diagnosed at over 15 years of age: an analysis of a Japanese nationwide survey.
  • PURPOSE: Hirschsprung's disease (HD) is usually diagnosed in patients who are under 1 year of age, however, there are still several reports of adult HD cases.
  • We herein analyzed the data of HD patients collected over 30 years according to a nationwide survey in Japan.
  • METHODS: The data of HD patients over 15 years of age were thus selected in three phases, namely from 1978 to 1982, from 1988 to 1992, and from 1998 to 2002.
  • CONCLUSIONS: Twenty-seven HD patients diagnosed over 15 years of age were analyzed.
  • However, further attention is still required in adult patients who are present with persistent intestinal obstruction of unknown etiology.
  • [MeSH-major] Hirschsprung Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Japan. Male. Middle Aged. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Hirschsprung's disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2005 Jan;40(1):197-201; discussion 201-2 [15868585.001]
  • [Cites] J Nippon Med Sch. 2005 Apr;72(2):113-20 [15940019.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 May;42(5):496-505 [16707970.001]
  • [Cites] J Am Coll Surg. 1998 Dec;187(6):577-83 [9849729.001]
  • (PMID = 19690873.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A: Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant; 2010 Dec;25(12):3996-4002
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has been suggested that hepcidin may be useful as a tool for managing iron therapy in haemodialysis (HD) patients on erythropoiesis-stimulating agents (ESA).
  • METHODS: We used SELDI-TOF mass spectrometry assay to measure serum hepcidin-25 (Hep-25) and hepcidin-20 (Hep-20) in 56 adult HD patients on maintenance ESA to assess their ability to predict haemoglobin (Hb) response after 1 g intravenous iron (62.5 mg ferric gluconate at 16 consecutive dialysis sessions) and their relationship with markers of iron status, inflammation and erythropoietic activity.
  • CONCLUSIONS: Although our study suggests an important role for hepcidin in regulating iron homeostasis in HD patients on ESA, our findings do not support its utility as a predictor of iron needs, offering no advantage over established markers of iron status.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20538788.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP06213
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Biomarkers; 0 / HAMP protein, human; 0 / Hematinics; 0 / Hemoglobins; 0 / Hepcidins; E1UOL152H7 / Iron
  •  go-up   go-down


22. Segura-Ortí E: [Exercise in haemodyalisis patients: a literature systematic review]. Nefrologia; 2010;30(2):236-46
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ejercicio en pacientes en hemodiálisis: revisión sistemática de la literatura.
  • Exercise as a therapeutic tool used in End-stage renal disease patients (ESRD) in hemodialysis (HD) is not routinately applied, as it occurs with cardiac or respiratory patients.
  • 1) to systematically review the literature of exercise training on adult HD patients or patients at a pre-HD stage;.
  • 3) to recommend requirements of future research in order to include exercise prescription in the HD patients treatment.
  • Randomized Controlled Trials on aerobic, strength and combined programs for HD patients were selected.
  • Future studies should clarify which out of the three modalities results in higher benefits for HD patients.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Exercise. Exercise Tolerance. Female. Humans. Male. Middle Aged. Oxygen Consumption. Quality of Life. Randomized Controlled Trials as Topic / statistics & numerical data. Research Design. Resistance Training. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098466.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 50
  •  go-up   go-down


23. Tsouchnikas I, Tsilipakou M, Daniilidis M, Kyriazis G, Pasadakis P, Parapanissiou E, Vargemezis V, Tsakiris D: Effect of iron loading on peripheral blood lymphocyte subsets and on circulating cytokine levels in iron-depleted hemodialysis patients receiving erythropoietin. Nephron Clin Pract; 2007;107(3):c97-102
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: High doses of iron are recommended intravenously in iron-depleted hemodialysis (HD) patients receiving recombinant erythropoietin (EPO).
  • The aim of this study was to evaluate the effect of iron load on peripheral blood lymphocytes subsets and on circulating cytokine levels in HD iron depleted patients, treated with EPO.
  • METHODS: We studied 19 stable adult HD patients, 12 males, with a mean age 59 +/- 11 years and mean HD duration 24 +/- 14 months.
  • The administered dose of iron was infused intravenously (1,000 mg iron sucrose) in 10 doses, during 10 consecutive HD sessions.
  • Patients were screened before the commencement of the HD session on two occasions, once prior to the first dose of iron and 2 days after the 10th dose.
  • CONCLUSION: Iron load in iron-deficient EPO-treated HD patients did not produce any changes in major lymphocyte subsets in peripheral blood, but it resulted in a significant increase of NKR+ T cells, a subpopulation important for local immune responses.
  • Iron load for a relatively short period improved anemia of HD patients and influenced the levels of the circulating IL-2, which may regulate factors affecting the survival of patients.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Iron.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17890877.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cytokines; 11096-26-7 / Erythropoietin; E1UOL152H7 / Iron
  •  go-up   go-down


24. Swarnalatha G, Ram R, Neela P, Naidu MU, Dakshina Murty KV: Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl; 2010 Sep;21(5):852-8
Hazardous Substances Data Bank. N-ACETYLCYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the contribution of injectable iron administered to hemodialysis (HD) patients in causing oxidative stress and the beneficial effect of N-acetylcysteine (NAC) in reducing it, we studied in a prospective, double blinded, randomized controlled, cross over trial 14 adult HD patients who were randomized into two groups; one group received NAC in a dose of 600 mgs twice daily for 10 days prior to intravenous iron therapy and the other group received placebo.
  • We conclude that in our HD patients NAC reduced the oxidative stress before and after the administration of intravenous iron therapy in addition to the endothelial dysfunction induced by this treatment.
  • [MeSH-minor] Adult. Biomarkers / blood. C-Reactive Protein / metabolism. Cross-Over Studies. Double-Blind Method. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Endothelium, Vascular / physiopathology. Female. Glucaric Acid. Humans. India. Infusions, Intravenous. Lipid Peroxidation / drug effects. Male. Malondialdehyde / blood. Middle Aged. Placebo Effect. Plethysmography. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814119.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Ferric Compounds; 0 / Hematinics; 4Y8F71G49Q / Malondialdehyde; 9007-41-4 / C-Reactive Protein; FZ7NYF5N8L / ferric oxide, saccharated; QLZ991V4A2 / Glucaric Acid; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


25. Klekawka T, Balwierz W, Moryl-Bujakowska A, Stanuch H, Matysiak M, Rokicka-Milewska R, Sopyło B, Kołakowska-Mrozowska B, Krenke K, Chybicka A, Chaber R, Sońita-Jakimczyki D, Janik-Moszants A, Wachowiak J, Kaczmarek-Kanold M, Kowalczyk J, Odój T, Balcerska A, Adamkiewicz-Drozyińska E, Wysocki M, Koltan A, Krawczuk-Rybako M, Muszyńska-Rosłan K, Stolarska M: [Does the residual mediastinal mass have prognostic significance in children with Hodgkin's disease (HD)?]. Przegl Lek; 2006;63(1):21-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does the residual mediastinal mass have prognostic significance in children with Hodgkin's disease (HD)?].
  • [Transliterated title] Czy obecność przetrwałej zmiany w sródpiersiu ma znaczenie prognostyczne w chorobie Hodgkina (HD) u dzieci?
  • Prognostic significance of residual mediastinal tumor mass in children treated for HD as well as the choice of the optimal management of these cases still remains unknown.
  • In years 1994-2001 in 10 PPLLSG participating centers 480 children (age 2-19.7 years) were treated for HD (stages I-IV).
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Follow-Up Studies. Humans. Prognosis. Retrospective Studies. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892894.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


26. Aanonsen NO: [Did Henrik Wergeland have AD/HD?]. Tidsskr Nor Laegeforen; 2008 Dec 18;128(24):2875-9
MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Did Henrik Wergeland have AD/HD?].
  • As I see it, his life is so full of events that indicate hyperactivity and impulsivity that I think it is legitimate to ask whether he would have received the diagnosis AD/HD (attention-deficit/ hyperactivity disorder) today.
  • [MeSH-minor] Adult. Child. History, 19th Century. Humans. Male. Norway. Poetry as Topic / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092970.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] Biography; English Abstract; Historical Article; Journal Article; Portraits
  • [Publication-country] Norway
  • [Personal-name-as-subject] Wergeland H
  •  go-up   go-down


27. Sleeper-Triplett J: The effectiveness of coaching for children and teens with AD/HD. Pediatr Nurs; 2008 Sep-Oct;34(5):433-5
MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effectiveness of coaching for children and teens with AD/HD.
  • Specialized AD/HD coaching can be a helpful service for families and children.
  • Readiness for AD/HD coaching is individual and depends on understanding cause and effect.
  • AD/HD coaches work with parents of very young children, with parents and children in the pre-teen years, and directly with teen clients.
  • AD/HD coaching for children and teens can lead to improved family life, better success in school, and optimum readiness for adult life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051849.001).
  • [ISSN] 0097-9805
  • [Journal-full-title] Pediatric nursing
  • [ISO-abbreviation] Pediatr Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


28. Maniadaki K, Sonuga-Barke E, Kakouros E, Karaba R: Maternal emotions and self-efficacy beliefs in relation to boys and girls with AD/HD. Child Psychiatry Hum Dev; 2005;35(3):245-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal emotions and self-efficacy beliefs in relation to boys and girls with AD/HD.
  • This study examined the impact of child gender on mothers' emotional responses to AD/HD, self-efficacy beliefs and perceived severity of AD/HD.
  • Mothers (N = 118) of pre-schoolers were presented with a vignette describing a typical boy or girl with AD/HD and then completed three scales relating to their emotional response to AD/HD behaviour, their sense of parenting efficacy and their attributions about the severity of problems described.
  • AD/HD behaviour elicited negative emotions and maternal self-efficacy was low, especially for male AD/HD.
  • These findings suggest that mothers of "normal" children have fixed negative emotions and low sense of self-efficacy towards a child with AD/HD and that these factors are key elements for change in the implementation of a therapeutic programme.
  • [MeSH-minor] Adult. Child. Child, Preschool. Factor Analysis, Statistical. Female. Greece. Humans. Male. Sex Factors

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Child Psychol Psychiatry. 1997 Jul;38(5):581-6 [9255702.001]
  • [Cites] Pediatrics. 1985 Nov;76(5):801-9 [4058990.001]
  • [Cites] Child Dev. 1982 Aug;53(4):991-1003 [7128264.001]
  • [Cites] J Child Psychol Psychiatry. 1993 Jul;34(5):715-28 [8340440.001]
  • [Cites] Pediatrics. 2003 May;111(5 Pt 2):1232-7 [12728144.001]
  • [Cites] Psychol Rev. 1985 Oct;92(4):548-73 [3903815.001]
  • [Cites] Child Dev. 1982 Oct;53(5):1371-81 [7140436.001]
  • [Cites] Dev Psychol. 1997 Sep;33(5):861-8 [9300219.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1706-14 [9401332.001]
  • [Cites] J Abnorm Child Psychol. 1996 Oct;24(5):555-69 [8956084.001]
  • [Cites] Child Psychiatry Hum Dev. 1991 Winter;22(2):111-28 [1800023.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Aug;36(8):1036-45 [9256583.001]
  • [Cites] Dev Psychopathol. 1999 Summer;11(3):607-28 [10532627.001]
  • [Cites] Psychol Bull. 1991 Jul;110(1):3-25 [1891517.001]
  • [Cites] J Abnorm Child Psychol. 1996 Feb;24(1):85-104 [8833030.001]
  • [Cites] Child Dev. 1991 Oct;62(5):918-29 [1756667.001]
  • [Cites] J Abnorm Child Psychol. 2000 Dec;28(6):543-53 [11104316.001]
  • [Cites] Dev Psychopathol. 2000 Winter;12(1):23-45 [10774594.001]
  • [Cites] Clin Child Fam Psychol Rev. 2001 Sep;4(3):183-207 [11783738.001]
  • [Cites] Monogr Soc Res Child Dev. 1981;46(1):1-82 [7242540.001]
  • [Cites] Br J Clin Psychol. 1998 Nov;37 ( Pt 4):441-9 [9856297.001]
  • [Cites] Child Care Health Dev. 2003 Nov;29(6):433-40 [14616900.001]
  • [Cites] J Exp Child Psychol. 2000 Jun;76(2):89-103 [10788304.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2001 Nov;40(11):1337-45 [11699809.001]
  • [Cites] J Clin Child Psychol. 2000 Mar;29(1):17-29 [10693029.001]
  • [Cites] Harv Rev Psychiatry. 1994 Jan-Feb;1(5):271-87 [9384859.001]
  • [Cites] J Abnorm Child Psychol. 2000 Dec;28(6):569-83 [11104318.001]
  • [Cites] J Abnorm Child Psychol. 2002 Dec;30(6):541-53 [12481970.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2002 Jun;41(6):703-11 [12049445.001]
  • (PMID = 15731889.001).
  • [ISSN] 0009-398X
  • [Journal-full-title] Child psychiatry and human development
  • [ISO-abbreviation] Child Psychiatry Hum Dev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Stout JC, Weaver M, Solomon AC, Queller S, Hui S, Johnson SA, Gray J, Beristain X, Wojcieszek J, Foroud T: Are cognitive changes progressive in prediagnostic HD? Cogn Behav Neurol; 2007 Dec;20(4):212-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are cognitive changes progressive in prediagnostic HD?
  • OBJECTIVE: To characterize neurocognitive signs of disease progression in prediagnosis and early Huntington disease (HD) and compare the sensitivity of 2 disease staging classification schemes for detecting these signs.
  • METHODS: Three hundred and six individuals at-risk for or recently diagnosed with HD completed the Unified Huntington's Disease Rating Scale, genetic testing, and a neurocognitive battery.
  • Two schemes were used to estimate latency to onset of disease.
  • Effect sizes were compared to assess the relative sensitivity of the 2 schemes for detecting signs of disease progression.
  • CONCLUSIONS: Neurocognitive function is not uniformly affected in prediagnosis and early HD; individuals near to their estimated age of diagnosis have cognitive signs similar to HD, whereas individuals far from estimated diagnosis appear cognitively normal.
  • Classification schemes that incorporate both genetic and phenotypic information may be more sensitive for tracking neurocognitive signs of disease progression.
  • [MeSH-major] Cognition Disorders / diagnosis. Huntington Disease / diagnosis. Neuropsychological Tests / statistics & numerical data
  • [MeSH-minor] Adult. Early Diagnosis. Female. Genetic Predisposition to Disease / genetics. Genetic Testing. Humans. Male. Middle Aged. Nerve Tissue Proteins / genetics. Neurologic Examination. Nuclear Proteins / genetics. Phenotype. Psychometrics. Reference Values. Trinucleotide Repeats

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091069.001).
  • [ISSN] 1543-3641
  • [Journal-full-title] Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
  • [ISO-abbreviation] Cogn Behav Neurol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR-00750; United States / NINDS NIH HHS / NS / N01-NS-3-2357; United States / NINDS NIH HHS / NS / R01 NS042659
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


30. Maniadaki K, Sonuga-Barke E, Kakouros E: Adults' self-efficacy beliefs and referral attitudes for boys and girls with AD/HD. Eur Child Adolesc Psychiatry; 2006 Mar;15(3):132-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adults' self-efficacy beliefs and referral attitudes for boys and girls with AD/HD.
  • Males with Attention Deficit/Hyperactivity Disorder (AD/HD) are referred to specialists significantly more frequently than females.
  • The aim of this study was to examine differences in mothers' and prospective educators' self-efficacy beliefs and severity perceptions towards boys and girls with AD/HD and to explore the inter-relationships between those perceptions and referral judgements.
  • One hundred and fifteen female prospective preschool educators and 118 mothers of boys and girls aged 4-6, enrolled in kindergartens in Athens completed a questionnaire that: (a) presented a vignette describing a typical boy or girl with AD/HD, and (b) was followed by two scales exploring severity perceptions and self-efficacy beliefs with reference to the child described in the vignette.
  • Mothers' sense of self-efficacy was higher than educators' and both samples had higher sense of self-efficacy towards girls with AD/HD than boys.
  • To conclude, adults' differentiated perceptions of severity of AD/HD in boys and girls, which might be influenced by their own limited self-efficacy beliefs, especially towards males, might account for a proportion of the differences in referral ratio of boys and girls with AD/HD.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Severity of Illness Index. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):966-75 [10434488.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1996 Feb;35(2):215-22 [8720631.001]
  • [Cites] J Child Psychol Psychiatry. 1997 Jul;38(5):581-6 [9255702.001]
  • [Cites] Pediatrics. 1985 Nov;76(5):801-9 [4058990.001]
  • [Cites] J Abnorm Child Psychol. 1996 Oct;24(5):555-69 [8956084.001]
  • [Cites] Child Psychiatry Hum Dev. 1991 Winter;22(2):111-28 [1800023.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Aug;36(8):1036-45 [9256583.001]
  • [Cites] J Abnorm Psychol. 1999 Feb;108(1):24-41 [10066990.001]
  • [Cites] J Child Psychol Psychiatry. 1990 Mar;31(3):437-46 [2318924.001]
  • [Cites] Child Psychiatry Hum Dev. 2005 Spring;35(3):245-63 [15731889.001]
  • [Cites] J Abnorm Child Psychol. 1993 Oct;21(5):519-33 [8294651.001]
  • [Cites] J Consult Clin Psychol. 1989 Dec;57(6):710-8 [2600241.001]
  • [Cites] Monogr Soc Res Child Dev. 1981;46(1):1-82 [7242540.001]
  • [Cites] Child Care Health Dev. 2003 Nov;29(6):433-40 [14616900.001]
  • [Cites] Am J Psychiatry. 1991 Jan;148(1):112-7 [1984694.001]
  • [Cites] Neurosci Biobehav Rev. 2000 Jan;24(1):137-41 [10654670.001]
  • (PMID = 16424963.001).
  • [ISSN] 1018-8827
  • [Journal-full-title] European child & adolescent psychiatry
  • [ISO-abbreviation] Eur Child Adolesc Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Sawaki R, Katayama J: Severity of AD/HD symptoms and efficiency of attentional resource allocation. Neurosci Lett; 2006 Oct 16;407(1):86-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severity of AD/HD symptoms and efficiency of attentional resource allocation.
  • This study investigated the mechanism that underlies the inefficient allocation of attentional resources in Attention-Deficit/Hyperactivity Disorder (AD/HD).
  • The P300 event-related brain potential (ERP) was elicited from 24 healthy adults using a visual three-stimulus oddball paradigm (standard, 70%; target, 15%; non-target, 15%) and the degree of their AD/HD symptoms was assessed by using AD/HD symptom scales.
  • The correlation analysis revealed a strong positive correlation between the AD/HD symptom score and the P300 amplitude ratio in the typical condition (r=.80), while only a weak positive correlation was observed in the novel condition (r=.23).
  • The present study found that the commonality of task-relevant and task-irrelevant information, rather than the stimulus novelty of task-irrelevant information, induces the inefficient allocation of attentional resources in AD/HD.
  • [MeSH-minor] Adult. Analysis of Variance. Brain Mapping. Electroencephalography / methods. Female. Humans. Male. Photic Stimulation / methods. Reaction Time / physiology. Severity of Illness Index. Task Performance and Analysis

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949203.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


32. Henley SM, Wild EJ, Hobbs NZ, Warren JD, Frost C, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ: Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia; 2008;46(8):2152-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective emotion recognition in early HD is neuropsychologically and anatomically generic.
  • Huntington's disease (HD) is an inherited neurodegenerative disorder that classically presents with motor, cognitive and psychiatric symptoms.
  • Deficits in emotion recognition impact significantly on the lives of HD patients and their families and thus it is important to clarify the onset and pattern of impairment.
  • This study investigated facial emotion recognition in a large cohort of early HD patients, and premanifest gene-carriers.
  • Forty patients with early HD, 21 premanifest gene carriers and 20 controls were assessed using 24 faces from the Ekman Pictures of Facial Affect, and volumetric brain MRI.
  • The HD group was significantly worse than controls at recognising, surprise, disgust, anger and fear, and worse than the premanifest group at recognising disgust and anger.
  • When patient data were expressed as z-scores, recognition of anger was significantly worse than disgust in the early HD group.
  • Even in early HD there is a wide-ranging impairment in recognition of negative emotions denoting 'threat'.
  • [MeSH-major] Cognition Disorders / etiology. Emotions / physiology. Facial Expression. Huntington Disease. Pattern Recognition, Visual / physiology
  • [MeSH-minor] Adult. Analysis of Variance. Brain Mapping. Female. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Middle Aged. Neuropsychological Tests. Trinucleotide Repeat Expansion / genetics

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407301.001).
  • [ISSN] 0028-3932
  • [Journal-full-title] Neuropsychologia
  • [ISO-abbreviation] Neuropsychologia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / G90/86; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / / G0601846; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


33. Barrios FA, Gonzalez L, Favila R, Alonso ME, Salgado PM, Diaz R, Fernandez-Ruiz J: Olfaction and neurodegeneration in HD. Neuroreport; 2007 Jan 8;18(1):73-6
MedlinePlus Health Information. consumer health - Taste and Smell Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfaction and neurodegeneration in HD.
  • It is not known, however, whether the olfactory deterioration is caused by a common neural deficit, or whether it is unique to each disease.
  • We report here the effect of degeneration of different brain structures on olfactory impairment in Huntington's disease as determined by voxel-based morphometric analysis.
  • Although various neuroimaging studies have shown previously that the caudate nucleus is involved in olfaction, this is the first demonstration that it is related to an olfactory dysfunction in a neurodegenerative disease.
  • [MeSH-major] Huntington Disease / complications. Neurodegenerative Diseases / etiology. Olfaction Disorders / etiology. Smell / physiology
  • [MeSH-minor] Adult. Brain / pathology. Case-Control Studies. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Degenerative Nerve Diseases.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259864.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Andrikos E, Tseke P, Balafa O, Pappas M: Five-year survival in comparable HD and PD patients: one center's experience. Int J Artif Organs; 2008 Aug;31(8):737-41
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year survival in comparable HD and PD patients: one center's experience.
  • Several studies have yielded conflicting results regarding morbidity and mortality in peritoneal dialysis (PD) and hemodialysis (HD) patients.
  • We performed a retrospective analysis in end-stage renal disease (ESRD) patients in our department, who were equally distributed between HD and PD, in order to compare 5-year survival probabilities and hospitalization rates in the two modalities.
  • Of the total 94 new ESRD patients who initiated dialysis in our department from January 1995 to December 2000, 48 were allocated to PD and 46 to HD.
  • There were no significant differences regarding demographics and serious co-morbidities upon dialysis initiation between HD and PD patients.
  • Unadjusted 5-year survival probability in as-treated analysis was higher in PD patients (0.79 vs 0.6, p=0.04), whereas there was no significant difference in intent-to-treat analysis between HD and PD patients (p=0.5).
  • Despite the small number of patients included in our study, it seems that when HD and PD are both available in one department they have equivalent results regarding morbidity and mortality rates.
  • Therefore we suggest that, when possible, PD and HD should be equally offered to all ESRD patients.
  • [MeSH-minor] Adult. Aged. Female. Hospitalization. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825647.001).
  • [ISSN] 0391-3988
  • [Journal-full-title] The International journal of artificial organs
  • [ISO-abbreviation] Int J Artif Organs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


35. Wheeler VC, Persichetti F, McNeil SM, Mysore JS, Mysore SS, MacDonald ME, Myers RH, Gusella JF, Wexler NS, US-Venezuela Collaborative Research Group: Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet; 2007 Nov;44(11):695-701
MedlinePlus Health Information. consumer health - Huntington's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with HD CAG repeat instability in Huntington disease.
  • BACKGROUND: The Huntington disease (HD) CAG repeat exhibits dramatic instability when transmitted to subsequent generations.
  • The instability of the HD disease allele in male intergenerational transmissions is reflected in the variability of the CAG repeat in DNA from the sperm of male carriers of the HD gene.
  • RESULTS: In this study, we used a collection of 112 sperm DNAs from male HD gene-positive members of a large Venezuelan cohort to investigate the factors associated with repeat instability.

  • Genetic Alliance. consumer health - Huntington disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2004 Jan 27;62(2):269-74 [14745066.001]
  • [Cites] Hum Mol Genet. 2003 Dec 15;12(24):3359-67 [14570710.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503 [14993615.001]
  • [Cites] Hum Mol Genet. 2004 Aug 15;13(16):1815-25 [15198993.001]
  • [Cites] Am J Hum Genet. 1987 Aug;41(2):218-48 [3618593.001]
  • [Cites] Annu Rev Neurosci. 1991;14:503-29 [1827708.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):398-403 [8401589.001]
  • [Cites] Hum Mol Genet. 1993 Dec;2(12):2063-7 [8111374.001]
  • [Cites] J Med Genet. 1993 Dec;30(12):1003-7 [8133495.001]
  • [Cites] Nat Genet. 1994 Apr;6(4):409-14 [8054984.001]
  • [Cites] J Med Genet. 1994 May;31(5):377-82 [8064815.001]
  • [Cites] Hum Mol Genet. 1995 Feb;4(2):189-95 [7757066.001]
  • [Cites] Clin Genet. 1995 Mar;47(3):113-7 [7634532.001]
  • [Cites] Am J Hum Genet. 1995 Aug;57(2):343-50 [7668260.001]
  • [Cites] Hum Mol Genet. 1995 Sep;4(9):1519-26 [8541834.001]
  • [Cites] Hum Mol Genet. 1997 May;6(5):775-9 [9158152.001]
  • [Cites] Am J Hum Genet. 1998 Sep;63(3):711-6 [9718331.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):173-83 [9931325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1823-5 [10051552.001]
  • [Cites] DNA Repair (Amst). 2007 Jun 1;6(6):789-96 [17293170.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9389-91 [14688268.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):471-3 [10581038.001]
  • [Cites] Hum Mol Genet. 2000 Nov 1;9(18):2767-75 [11063736.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):191-8 [11809728.001]
  • [Cites] Hum Mol Genet. 2003 Jan 1;12(1):41-50 [12490531.001]
  • [Cites] Am J Hum Genet. 2003 Feb;72(2):454-64 [12529854.001]
  • [Cites] Hum Mol Genet. 2003 Feb 1;12(3):273-81 [12554681.001]
  • [Cites] EMBO J. 2003 May 1;22(9):2264-73 [12727892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8834-8 [12857955.001]
  • [CommentIn] J Med Genet. 2008 Nov;45(11):766 [18978336.001]
  • (PMID = 17660463.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS016367-28; United States / NINDS NIH HHS / NS / NS049206-04; United States / NINDS NIH HHS / NS / NS016367-28; United States / NINDS NIH HHS / NS / P50 NS016367; United States / NINDS NIH HHS / NS / R01 NS049206; United States / NINDS NIH HHS / NS / R01 NS049206-04; United States / NINDS NIH HHS / NS / NS049206
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  • [Other-IDs] NLM/ NIHMS110572; NLM/ PMC2705129
  •  go-up   go-down


36. Matsuura N, Hashimoto T, Toichi M: The relationship between self-esteem and AD/HD characteristics in the serious juvenile delinquents in Japan. Res Dev Disabil; 2009 Sep-Oct;30(5):884-90
MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between self-esteem and AD/HD characteristics in the serious juvenile delinquents in Japan.
  • The AD/HD-YSR attention deficit score was negatively correlated with the self-esteem score on admission but was not associated with the self-esteem score at the time of parole.
  • Our results were suggested that total AD/HD-YSR score in the high self-esteem group was lower than that in the other groups.
  • Our cross-sectional surveys have shown an association between the AD/HD-YSR score and self-esteem, suggesting the influences of developmental problems on self-esteem.
  • [MeSH-minor] Adolescent. Humans. Japan. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200690.001).
  • [ISSN] 1873-3379
  • [Journal-full-title] Research in developmental disabilities
  • [ISO-abbreviation] Res Dev Disabil
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Mano S, Uno H: [Relationship between characteristic behaviors of children with AD/HD and mothers' parenting styles]. No To Hattatsu; 2007 Jan;39(1):19-24
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between characteristic behaviors of children with AD/HD and mothers' parenting styles].
  • Previous studies have revealed that mothers of children with attention-deficit/hyperactivity disorder (AD/HD) have an authoritarian parenting style.
  • To clarify this psychological process, the present study examined the hypothesis that the characteristic behaviors of children with AD/HD initially increase the mothers' parenting stress, which influences their parenting style.
  • Thirty-six mothers of children with AD/HD (children's mean age: 8.1 years) and the same number of controls (children's mean age: 8.4 years) participated in the present study.
  • The results indicated that the mothers of children with AD/HD had significantly higher scores than controls for all parenting stress items and negative parenting style variables (dissatisfaction, reproach, strictness, interference, inconsistency and disagreement of 10 attitudes).
  • Stepwise multiple regression analysis revealed that the characteristic behaviors of children with AD/HD were associated with the degree of attachment in mothers, which was related to the strict and reproachful parenting style in the AD/HD group.
  • These results suggest that mothers of children with AD/HD are likely to have a strict and reproachful parenting style as a result of a lack of attachment with the child.
  • [MeSH-minor] Adult. Child. Female. Humans. Male. Mother-Child Relations

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • MedlinePlus Health Information. consumer health - Parenting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228814.001).
  • [ISSN] 0029-0831
  • [Journal-full-title] No to hattatsu. Brain and development
  • [ISO-abbreviation] No To Hattatsu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E, Predict-HD Investigators of the Huntington Study Group: Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol; 2006 Jun;63(6):883-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparing for preventive clinical trials: the Predict-HD study.
  • OBJECTIVE: To examine measures that may be associated with disease in the largest cohort ever recruited of prediagnosed individuals carrying the gene expansion for Huntington disease (HD).
  • DESIGN: The Predict-HD study is a multicenter observational research study in progress at 17 sites in the United States, 4 in Canada, and 3 in Australia.
  • SETTING: Genetics and HD outpatient clinics.
  • PARTICIPANTS: Five hundred five at-risk individuals who had previously undergone elective DNA analyses for the CAG expansion in the HD gene (predictive testing) and did not currently have a clinical diagnosis of HD.
  • MAIN OUTCOME MEASURES: Basal ganglia volumes on magnetic resonance images, estimated probability of diagnosis (based on CAG repeat length), performances on 21 standardized cognitive tasks, total scores on 3 scales of psychiatric distress, and motor diagnosis based on the Unified Huntington's Disease Rating Scale.
  • RESULTS: Several variables showed progressive decline as the diagnostic ratings advanced toward manifest disease.
  • Estimated probability of diagnosis was associated with Unified Huntington's Disease Rating Scale prediagnostic stages and varied from 15% in persons with no motor abnormalities to nearly 40% in those with abnormalities suggestive of probable disease.
  • Striatal volumes, cognitive performances, and even psychiatric ratings declined significantly with motor manifestations of disease.
  • Longitudinal study is critical to further validate possible markers for prediagnosed HD.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769871.001).
  • [ISSN] 0003-9942
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS040068; United States / PHS HHS / / 40068; United States / PHS HHS / / 00059; United States / PHS HHS / / 16375; United States / PHS HHS / / 01579
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Pagot-Mathis V, Benouaich X, Mathis A, Rico-Lattes I, Dumoulin A: [Management of complicated retinal detachment using a heavy silicon oil as temporary tamponade]. J Fr Ophtalmol; 2006 Feb;29(2):137-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tamponnement interne par huile de silicone lourde (Oxane Hd) dans les décollements de rétine complexes.
  • CONCLUSION: Heavy silicon oil (Oxane Hd) is as safe and effective as standard silicon oil in the treatment of selected retinal detachment, but intraocular manipulations are quite difficult.
  • A prospective study is necessary to compare the efficacy of Oxane Hd and standard silicon oil in selected cases of retinal detachment with inferior breaks and in cases of large inferior retinectomy.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / epidemiology. Retreatment. Time Factors

  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523154.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Silicone Oils
  •  go-up   go-down


40. Ang GS, Murphy AL, Ng WS, Atta HR: Oxane HD and retinal detachment surgery in routine clinical practice. Ophthalmologica; 2010;224(6):347-53
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxane HD and retinal detachment surgery in routine clinical practice.
  • BACKGROUND/AIMS: To assess the outcomes and complications of endotamponade with Oxane HD following retinal detachment repair.
  • METHODS: Retrospective consecutive case series of inferior retinal detachment with Oxane HD endotamponade within a 3-year period.
  • The mean Oxane HD endotamponade and follow-up durations were 27 ± 38 and 66 ± 39 weeks, respectively.
  • Of the 14 eyes requiring intraoperative perfluorodecalin, 12 (85.7%) developed complications; all 5 (100%) eyes with direct exchange of perfluorodecalin with Oxane HD developed complications.
  • CONCLUSION: Although useful for inferior retinal detachments, Oxane HD was associated with a relatively high rate of emulsification when compared to other series.
  • Our series also suggests that prior use of perfluorodecalin intraoperatively, and in particular direct exchange of perfluorodecalin with Oxane HD, may be associated with an increased risk of intraocular complications.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorocarbons / administration & dosage. Fluorocarbons / adverse effects. Follow-Up Studies. Humans. Incidence. Intraoperative Care. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Risk Assessment. Treatment Outcome. Visual Acuity. Vitreoretinopathy, Proliferative / complications. Vitreous Body. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20453541.001).
  • [ISSN] 1423-0267
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Fluorocarbons; 0 / Silicone Oils; 0 / oxane HD; 54A06VV62N / perfluorodecalin
  •  go-up   go-down


41. Gayán J, Brocklebank D, Andresen JM, Alkorta-Aranburu G, US-Venezuela Collaborative Research Group, Zameel Cader M, Roberts SA, Cherny SS, Wexler NS, Cardon LR, Housman DE: Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet Epidemiol; 2008 Jul;32(5):445-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds.
  • The age of onset of Huntington's disease (HD) is inversely correlated with the CAG length in the HD gene.
  • The CAG repeat length accounts for 70% of the variability in HD age of onset.
  • However, 90% of individuals worldwide with expanded alleles possess between 40 and 50 CAG repeat lengths in their HD gene.
  • Targeted candidate gene studies and a genome scan have suggested some loci as potential modifiers of the age of onset of HD.
  • We analyzed the large Venezuelan kindreds in which the HD gene was originally identified.
  • All these regions harbor candidate genes that are potential HD modifier genes.
  • Finding these modifier genes can reveal accessible and promising new therapeutic pathways and targets to ameliorate and cure HD.
  • [MeSH-major] Genetic Linkage. Huntington Disease / genetics
  • [MeSH-minor] Adult. Age of Onset. Chromosome Mapping. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 6. Genome, Human. Humans. Middle Aged. Pedigree. Venezuela / epidemiology

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18481795.001).
  • [ISSN] 1098-2272
  • [Journal-full-title] Genetic epidemiology
  • [ISO-abbreviation] Genet. Epidemiol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601887; United States / NEI NIH HHS / EY / EY-12562; United States / NCRR NIH HHS / RR / U54 RR020278
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


42. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, Predict-HD Investigators and Coordinators of the Huntington Study Group: Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry; 2008 Aug;79(8):874-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Huntington's disease decades before diagnosis: the Predict-HD study.
  • OBJECTIVE: The objective of the Predict-HD study is to use genetic, neurobiological and refined clinical markers to understand the early progression of Huntington's disease (HD), prior to the point of traditional diagnosis, in persons with a known gene mutation.
  • Here we estimate the approximate onset and initial course of various measurable aspects of HD relative to the time of eventual diagnosis.
  • METHODS: We studied 438 participants who were positive for the HD gene mutation, but did not yet meet the diagnostic criteria for HD and had no functional decline.
  • CONCLUSIONS: These findings from the Predict-HD study suggest the approximate time scale of measurable disease development, and suggest candidate disease markers for use in preventive HD trials.
  • [MeSH-major] Genetic Testing. Huntington Disease / diagnosis. Magnetic Resonance Imaging. Nerve Tissue Proteins / genetics. Neurologic Examination. Neuropsychological Tests. Nuclear Proteins / genetics
  • [MeSH-minor] Adult. Aged. Attention. Caudate Nucleus / pathology. Chromosomes, Human, Pair 4 / genetics. Early Diagnosis. Female. Humans. Huntingtin Protein. Longitudinal Studies. Male. Mental Recall. Middle Aged. Olfaction Disorders / diagnosis. Olfaction Disorders / genetics. Predictive Value of Tests. Probability. Putamen / pathology. Reaction Time. Trinucleotide Repeats. Verbal Learning


43. Mariotti M, Castiglioni S, Maier JA: Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP. J Cell Biochem; 2006 May 15;98(2):301-8
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP.
  • By RNA fingerprinting, we found that Tat upregulates the tyrosine phosphatase HD-PTP mRNA in a human endothelial cell line.
  • At the moment, little is known about HD-PTP.
  • We here show that HD-PTP is highly conserved through evolution from yeast to man, and is ubiquitously distributed in adult and fetal tissues.
  • HD-PTP is expressed in human cell lines derived from different tumors, but the mRNA levels do not appear to correlate with the malignant phenotype of the cells.
  • HD-PTP mRNA was also detected in cell lines derived from tumors that develop in BKV/Tat-transgenic mice.
  • Interestingly, a relation exists between the amounts of secreted Tat and the levels of HD-PTP mRNA.
  • HD-PTP encodes a 185-kDa protein which is expressed in human endothelial from the umbilical cord and in human Kaposi-spindle cells.
  • Tat-induction of HD-PTP mRNA parallels only with a slight increase of the protein, which occurs after 24 and 48 h of incubation in the presence of Tat.
  • These results suggest that HD-PTP amounts might be regulated both at the transcriptional and post-transcriptional levels.
  • [MeSH-minor] Adult. Animals. Biomarkers, Tumor / metabolism. Brain / embryology. Brain / metabolism. Cell Line. Gene Expression. Humans. Male. Mice. Mice, Transgenic. Muscle, Skeletal / metabolism. Myocardium / metabolism. Placenta / metabolism. Protein Tyrosine Phosphatase, Non-Receptor Type 1. Protein Tyrosine Phosphatases, Non-Receptor. RNA, Messenger / isolation & purification. RNA, Messenger / metabolism. Tissue Distribution. Up-Regulation

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16408268.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gene Products, tat; 0 / RNA, Messenger; EC 3.1.3.48 / PTPN23 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 1; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Protein Tyrosine Phosphatases, Non-Receptor
  •  go-up   go-down


44. Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS, I-RESPOND-HD Investigators of the Huntington Study Group: Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet; 2010 Jul;153B(5):1081-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study.
  • Data from the United States, Canada, and Australia were collected from 433 individuals at risk for Huntington disease (HD) who have tested either positive or negative for the gene that causes HD and family members of affected individuals who have a 50% risk for developing the disorder but remain untested.
  • Across all three countries, a total of 46.2% of respondents report genetic discrimination or stigma based on either their family history of HD or genetic testing for the HD gene mutation.
  • Despite a relatively low rate of perceived genetic discrimination in the areas of health insurance and employment, compared to the perception of discrimination and stigma in personal relationships, the cumulative burden of genetic discrimination across all domains of experience represents a challenge to those at risk for HD.
  • [MeSH-major] Health Surveys. Huntington Disease / genetics. Huntington Disease / psychology. International Cooperation. Perception. Prejudice
  • [MeSH-minor] Adult. Demography. Employment / legislation & jurisprudence. Female. Health Knowledge, Attitudes, Practice. Humans. Insurance, Health / legislation & jurisprudence. Male. Middle Aged

  • Genetic Alliance. consumer health - Huntington disease.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Mol Genet Med. 1993;3:139-58 [8220162.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Am J Med Genet. 1996 Aug 9;64(2):378-81 [8844087.001]
  • [Cites] Science. 1996 Oct 25;274(5287):621-4 [8849455.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):510-6 [15545747.001]
  • [Cites] Community Genet. 2004;7(4):161-8 [15692189.001]
  • [Cites] Univ PA Law Rev. 2001 May;149(5):1483-1505 [15732207.001]
  • [Cites] Genet Med. 2005 May-Jun;7(5):311-6 [15915082.001]
  • [Cites] Genet Med. 2006 Jan;8(1):33-42 [16418597.001]
  • [Cites] Arch Neurol. 2006 Jul;63(7):991-6 [16831969.001]
  • [Cites] Clin Genet. 2007 Mar;71(3):220-31 [17309644.001]
  • [Cites] Am J Med Genet A. 2007 Apr 1;143A(7):707-17 [17290434.001]
  • [Cites] Eur J Hum Genet. 2008 Mar;16(3):279-89 [17957229.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):320-5 [17948904.001]
  • [Cites] J Law Med Ethics. 1998 Fall;26(3):198-204, 178 [11066877.001]
  • [Cites] J Law Med Ethics. 2000 Fall;28(3):245-57 [11210377.001]
  • [Cites] Sci Eng Ethics. 1996 Jan;2(1):71-88 [11657787.001]
  • [Cites] J Adv Nurs. 2003 Apr;42(1):57-63 [12641812.001]
  • [Cites] McGill Law J. 2000 May;45(2):347-412 [12688286.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):835-47 [12695777.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):1175-80 [12809845.001]
  • [Cites] Clin Genet. 2008 Jul;74(1):20-30 [18492091.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80 [18096682.001]
  • [Cites] Genet Med. 2008 Sep;10(9):691-8 [18978681.001]
  • [Cites] Genet Med. 2008 Dec;10(12):869-73 [19092438.001]
  • [Cites] BMJ. 2009;338:b2175 [19509425.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408 [19548255.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1150-9 [20468062.001]
  • [Cites] Genet Med. 2001 Sep-Oct;3(5):354-8 [11545689.001]
  • [Cites] Lancet Neurol. 2004 Apr;3(4):249-52 [15039038.001]
  • [Cites] Clin Genet. 2004 Oct;66(4):311-7 [15355433.001]
  • [Cites] New Genet Soc. 2004 Aug;23(2):225-39 [15460616.001]
  • [Cites] Psychophysiology. 1979 Nov;16(6):572-81 [515298.001]
  • [Cites] Am J Law Med. 1991;17(1-2):109-44 [1831594.001]
  • [Cites] Am J Hum Genet. 1992 Mar;50(3):476-82 [1539589.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Med Care. 1993 Mar;31(3):247-63 [8450681.001]
  • [Cites] J Pers Soc Psychol. 1994 Dec;67(6):1063-78 [7815302.001]
  • (PMID = 20468061.001).
  • [ISSN] 1552-485X
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] eng
  • [Grant] United States / NHGRI NIH HHS / HG / R01 HG003330; United States / NHGRI NIH HHS / HG / R01 HG003330; United States / NINDS NIH HHS / NS / R01 NS040068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS422921; NLM/ PMC3593716
  • [Investigator] Adams W; Elbert M; Paulsen J; Williams J; Chiu E; Goh A; Yastrubetskaya O; Agarwal A; Rosenblatt A; Welsh C; Marder K; Wasserman P; Moskowitz C; Decolongon J; Raymond LA; Lipe H; Samii A; Williams P; Aylward E; Harrison JM; Jones RJ; Wood-Siverio C; Quaid K; Wesson M; Biglan K; Chesire A; Como P; Giambattista C; Guttman M; Sheinberg A; Singer A; Griffith J; McCusker E; Richardson K; Tempkin T; Wheelock VL; Johnson A; Linderholm W; Perlman S; Geschwind MD; Gooblar J; Guzijan M; Chua P; Komiti A; Panegyres P; Vuletich E; Woodman M
  •  go-up   go-down


45. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group: Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord; 2009 Sep 15;24(12):1763-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.
  • The PREDICT-HD study seeks to identify clinical and biological markers of Huntington's disease in premanifest individuals who have undergone predictive genetic testing.
  • Elevated total motor scores at baseline were associated with higher genetic probability of disease diagnosis in the near future (partial R(2) 0.14, P < 0.0001) and smaller striatal volumes (partial R(2) 0.15, P < 0.0001).
  • Even in this premanifest population, subtle motor abnormalities were associated with a higher probability of disease diagnosis and smaller striatal volumes.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80 [18096682.001]
  • [Cites] Biol Psychiatry. 2007 Dec 15;62(12):1341-6 [17481592.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):376-7 [16894093.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):394-9 [16855205.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):485-7 [16625001.001]
  • [Cites] Arch Neurol. 2006 Jun;63(6):883-90 [16769871.001]
  • [Cites] Psychiatry Res. 2005 Oct 30;140(1):55-62 [16199141.001]
  • [Cites] Neurology. 2005 Sep 13;65(5):745-7 [16157910.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 May;76(5):650-5 [15834021.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1715-21 [15569736.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jan-Feb;23(1):144-54 [10050826.001]
  • [Cites] Pediatr Neurol. 1997 Jul;17(1):37-43 [9308974.001]
  • [Cites] Arch Neurol. 1996 Dec;53(12):1293-6 [8970459.001]
  • [Cites] Comput Biomed Res. 1996 Jun;29(3):162-73 [8812068.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Mov Disord. 1995 Mar;10(2):211-4 [7753064.001]
  • [Cites] Neurology. 1994 May;44(5):823-8 [8190282.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Ann Neurol. 1992 Jan;31(1):69-75 [1531910.001]
  • [Cites] Mov Disord. 1990;5(2):93-9 [2139171.001]
  • [Cites] Neuroimage. 2003 Jun;19(2 Pt 1):233-45 [12814574.001]
  • [Cites] Clin Genet. 2004 Apr;65(4):267-77 [15025718.001]
  • [Cites] Neurology. 2004 Jul 13;63(1):66-72 [15249612.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):452-8 [10668713.001]
  • [Cites] Mov Disord. 2000 May;15(3):552-60 [10830423.001]
  • [Cites] J Clin Neurosci. 2000 Jan;7(1):38-41 [10847649.001]
  • [Cites] IEEE Trans Med Imaging. 2000 Mar;19(3):153-65 [10875700.001]
  • [Cites] Arch Neurol. 2000 Jul;57(7):1040-4 [10891987.001]
  • [Cites] Ann Neurol. 2001 Jan;49(1):29-34 [11198293.001]
  • [Cites] Neurology. 2001 Aug 28;57(4):658-62 [11524475.001]
  • [Cites] Comput Med Imaging Graph. 2002 Jul-Aug;26(4):251-64 [12074920.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1815-28 [12135972.001]
  • (PMID = 19562761.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS040068-09; United States / NINDS NIH HHS / NS / NS040068-09; United States / NINDS NIH HHS / NS / R01 NS040068; United States / NINDS NIH HHS / NS / NS40068; United States / NCATS NIH HHS / TR / UL1 TR000442; United States / NCRR NIH HHS / RR / S10 RR023392; United States / NCATS NIH HHS / TR / UL1 TR000040
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS274263; NLM/ PMC3048804
  • [Investigator] Ames D; Chiu E; Chua P; Yastrubetskaya O; Dingjan P; Drpaer K; Georgiou-Karistianis N; Goh A; Komiti A; Lemmon C; Paulson H; Bastic K; Conybeare R; Humphreys C; Nopoulos P; Rodnitzky R; Uc E; Beglinger L; Duff K; Magnotta VA; Doucette N; French S; Juhl A; Kuburas H; Mikos A; Reese B; Turner B; Van Der Heiden S; Raymond L; Decolongon J; Rosenblatt A; Ross C; Agarwal A; Gourley L; Shpritz B; Wajda K; Bakker A; Miller R; Mallonee W; Suter G; Palmer D; Addison J; Jones R; Harrison J; Greenamyre JT; Testa C; McCusker E; Griffith J; Bibb B; Hayes C; Richardson K; Samii A; Lipe H; Bird T; Logsdon R; Weaver K; Field K; Landwehrmeyer BG; Barth K; Niess A; Trautmann S; Ecker D; Held C; Guttman M; Elliott S; Fonariov Z; Giambattista C; Russell S; Sebastian J; Sethna R; Ip R; Shaddick D; Sheinberg A; Stober J; Perlman S; Carroll R; Johnson A; Jackson G; Geschwind MD; Guzijan M; Rose K; Warner T; Kloppel S; Burrows M; Andrews T; Rosser E; Tabrizi S; Golding C; Barker RA; Mason S; Smith E; Rosser A; Naji J; Price K; Handley OJ; Suchowersky O; Furtado S; Klimek ML; Kirstein D; Rosas D; Bennett M; Frishman J; Kaneko Y; Landau T; Lausier M; Muir L; Murphy L; Young A; Skeuse C; Balkema N; Hoogenboom W; Leveroni C; Sherman J; Zaleta A; Panegyres P; Connor C; Woodman M; Zombor R; Perlmutter J; Barton S; Kavanaugh M; Simpson SA; Keenan G; Ure A; Summers F; Craufurd D; Macleod R; Sollom A; Howard E; Quaid K; Wesson M; Wojcieszek J; Beristain X; Mazzoni P; Marder K; Williamson J; Moskowitz C; Wasserman P; Como P; Chesire A; Hickey C; Zimmerman C; Couniham T; Marshall F; Burton C; Wodarski M; Wheelock V; Tempkin T; Baynes K; Jankovic J; Hunter C; Ondo W; Martin C; Garcia de Yebenes J; Bascunana Garde M; Fatas M; Schwartz C; Fernandez Urdanibia J; Gonzalez Gordaliza C; Seeberger L; Diamond A; Judd D; Kasunic TL; Mellick L; Miracle D; Montellano S; Kumar R; Schneiders J; Nance M; Radtke D; Norberg D; Tupper D; Martin W; King P; Wieler M; Foster S; Sran S; Dubinsky R; Gray C; Switzer P; Paulsen J; Langbehn D; Johnson H; Aylward E; Biglan K; Kieburtz K; Oakes D; Shoulson I; Guttman M; Hayden M; Landwehrmeyer BG; Nance M; Ross C; Stout J; Blanchard S; Anderson C; Dudler A; Penziner E; Leserman A; Ludwig B; McAreavy B; Murray G; Nehl C; Vik S; Wang C; Werling C; Bourgeois K; Covert C; Daigneault S; Julian-Baros E; Meyers K; Rothenburgh K; Olsen B; Orme C; Ross T; Weber J; Zhao H; Stout JC; Queller S; Johnson SA; Campbell JC; Peters E; Carlozzi NE; Green T; Swain SN; Caughlin D; Ward-Bluhm B; Whitlock K; Paulsen J; Penziner E; Vik S; Agarwal A; Barnes A; Suter G; Jones R; Griffith J; Lipe H; Barth K; Fox M; Guzijan M; Zanko A; Naji J; Zombor R; Kavanaugh M; Chesire A; Julian-Baros E; Kayson E; Tempkin T; Nance M; Quaid K; Stout J; Paulsen J; Coryell W; Ross C; Kayson E; Shinaman A; Tempkin T; Nance M; Quaid K; Stout J; Erwin S
  •  go-up   go-down


46. Savini G, Carbonelli M, Parisi V, Barboni P: Effect of pupil dilation on retinal nerve fibre layer thickness measurements and their repeatability with Cirrus HD-OCT. Eye (Lond); 2010 Sep;24(9):1503-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of pupil dilation on retinal nerve fibre layer thickness measurements and their repeatability with Cirrus HD-OCT.
  • Using Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA, USA) three individual 200 × 200 cube optic disc scans were obtained before and after pupil dilation.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Humans. Male. Middle Aged. Mydriatics / administration & dosage. Prospective Studies. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489736.001).
  • [ISSN] 1476-5454
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mydriatics
  •  go-up   go-down


47. Meng Q, Zhang S, Cheng H, Chen X, Jin Y: Long-term outcomes of Oxane Hd as intraocular tamponade in the treatment of complicated retinal detachment. Graefes Arch Clin Exp Ophthalmol; 2010 Aug;248(8):1091-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of Oxane Hd as intraocular tamponade in the treatment of complicated retinal detachment.
  • BACKGROUND: To evaluate the efficacy and safety of heavy silicone oil Oxane Hd as intraocular tamponade in the treatment of complicated retinal detachment (RD).
  • Oxane Hd was used as intraocular tamponade.
  • RESULTS: The mean duration of Oxane Hd endotamponade was 87.9 +/- 10.4 days, and the mean follow-up time after Oxane Hd removal was 438.1 +/- 153.7 days.
  • The primary anatomical success rate after Oxane Hd removal was 87.5%, and with further intervention 97.5%.
  • CONCLUSIONS: Without a requirement for postoperative prone position, heavy silicone oil Oxane Hd is effective and safe for the treatment of complicated RD with inferior and posterior breaks.
  • Larger groups and a longer follow-up period will be included to further evaluate the efficacy with Oxane Hd in superior retinal breaks.
  • [MeSH-minor] Adult. Aged. Cataract / etiology. Combined Modality Therapy. Drainage / methods. Emulsions. Female. Follow-Up Studies. Humans. Intraocular Pressure. Laser Coagulation. Male. Middle Aged. Postoperative Complications. Prospective Studies. Retinal Perforations / drug therapy. Retinal Perforations / physiopathology. Retinal Perforations / surgery. Treatment Outcome. Visual Acuity / physiology. Vitrectomy / methods. Vitreoretinopathy, Proliferative / drug therapy. Vitreoretinopathy, Proliferative / physiopathology. Vitreoretinopathy, Proliferative / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Refract Surg. 1997 Jul-Aug;13(4):388-91 [9268940.001]
  • [Cites] Eur J Ophthalmol. 2000 Jul-Sep;10(3):189-97 [11071025.001]
  • [Cites] Br J Ophthalmol. 2005 Jun;89(6):662-5 [15923496.001]
  • [Cites] Ophthalmic Res. 2007;39(4):198-206 [17596752.001]
  • [Cites] Br J Ophthalmol. 2007 Oct;91(10):1379-81 [17431021.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2008 Oct;246(10):1383-9 [18587596.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2007 Aug;245(8):1097-105 [17219121.001]
  • [Cites] Arch Ophthalmol. 1997 Mar;115(3):335-44 [9076205.001]
  • [Cites] Retina. 2006 Oct;26(8):905-8 [17031291.001]
  • [Cites] Int Ophthalmol. 1999;23(1):17-24 [11008894.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):628-36 [16226515.001]
  • [Cites] Acta Ophthalmol. 2009 Nov;87(8):866-70 [18983619.001]
  • [Cites] Arch Ophthalmol. 2007 Sep;125(9):1161-7 [17846353.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):609-19 [16205937.001]
  • [Cites] Am J Ophthalmol. 2002 Jan;133(1):95-101 [11755844.001]
  • [Cites] Am J Ophthalmol. 2009 Mar;147(3):495-500 [19019339.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1633-5 [18546011.001]
  • [Cites] Ophthalmology. 1998 Sep;105(9):1587-97 [9754162.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):943-8 [18369656.001]
  • [Cites] Ophthalmology. 2006 Nov;113(11):2041-7 [16952397.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2009 Nov;247(11):1471-6 [19649646.001]
  • [Cites] Retina. 2003 Jun;23(3):335-42 [12824833.001]
  • [Cites] Eye (Lond). 2010 Jan;24(1):21-8 [19325573.001]
  • [Cites] Eur J Ophthalmol. 2007 Sep-Oct;17 (5):797-803 [17932858.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1153-7 [15983817.001]
  • [Cites] Am J Ophthalmol. 1991 Aug 15;112(2):159-65 [1867299.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1541-6 [18618126.001]
  • (PMID = 20306070.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Emulsions; 0 / Silicone Oils; 0 / oxane HD
  •  go-up   go-down


48. Posadzy-Małaczyńska A, Wanic-Kossowska M, Tykarski A, Czekalski S, Głuszek J, Kosch M: [Vascular stiffness in chronic renal failure patients treated by hemodialysis]. Pol Arch Med Wewn; 2005 Nov;114(5):1072-8
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Sztywnosć duzych naczyń u chorych z przewlekła niewydolnościa nerek leczonych zabiegami hemodializ (HD).
  • Cardiovascular disease is a major cause of morbidity in patients with end-stage renal failure.
  • In 20 chronic renal failure patients treated by hemodialysis (HD) we assessed the PWV of the carotic artery as well as artery diameter and distensibility, systolic pressure (SBP), diastolic pressure (DBP), pulse pressure (PP), and basal biochemical parameters and compared them with the values determined in 20 healthy controls of comparable age.
  • PWV and PP are significantly (p < 0.001, p < 0.05) higher and distensibility of the carotic artery was significantly lower (p < 0.001) compared to a control group SBP and DBP were < 140/90 mmHg in HD patients (high normotensive range) but were significantly (p < 0.05) higher than in a control group.
  • In HD patients PP was correlated with arterial distensibility r = -0.600 (p < 0.005), and systolic artery rice r = -0.408 (p < 0.05).
  • [MeSH-minor] Adult. Aorta / physiopathology. Blood Pressure / physiology. Cardiovascular Diseases / etiology. Cardiovascular Diseases / physiopathology. Cross-Sectional Studies. Elasticity. Female. Humans. Hypertrophy, Left Ventricular / etiology. Male. Pulsatile Flow / physiology. Renal Dialysis. Risk Factors. Vascular Capacitance. Vascular Resistance

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16789505.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


49. Avbersek-Luznik I, Balon BP, Rus I, Marc J: Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant; 2005 Mar;20(3):566-70
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
  • Since RANKL and osteoprotegerin (OPG) production in bone is influenced by parathyroid hormone (PTH), we measured serum RANKL and OPG concentrations in haemodialysis (HD) patients, who commonly hypersecrete PTH.
  • METHODS: RANKL, OPG, osteocalcin, intact PTH, bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase 5b and beta-CrossLaps (CTx) were measured in blood samples from 80 HD patients and 50 age-matched controls.
  • HD patients were stratified to tertiles according to their serum PTH levels: 29.3-103.0, 109.7-263.0 and 262.0-1700.0 pg/ml in the first, second and third tertiles, respectively.
  • RESULTS: Mean serum RANKL levels were 1.6 times higher in HD patients than in age-matched controls (1.36+/-0.39 vs 0.83+/-0.70 pmol/l; P<0.001).
  • CONCLUSIONS: Serum RANKL levels were significantly higher in HD patients than in healthy age-matched controls.
  • Therefore, the hypothesis that PTH increases bone resorption in HD patients through RANKL appears valid.
  • [MeSH-minor] Acid Phosphatase / blood. Adult. Aged. Alkaline Phosphatase / blood. Case-Control Studies. Collagen / blood. Female. Humans. Isoenzymes / blood. Male. Middle Aged. Osteocalcin / blood. Osteoprotegerin. Peptide Fragments / blood. RANK Ligand. Receptor Activator of Nuclear Factor-kappa B. Receptors, Tumor Necrosis Factor

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665031.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Isoenzymes; 0 / Membrane Glycoproteins; 0 / Osteoprotegerin; 0 / Parathyroid Hormone; 0 / Peptide Fragments; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF11A protein, human; 0 / TNFRSF11B protein, human; 0 / TNFSF11 protein, human; 0 / glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine; 104982-03-8 / Osteocalcin; 9007-34-5 / Collagen; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


50. van Mourik R, Oosterlaan J, Sergeant JA: The Stroop revisited: a meta-analysis of interference control in AD/HD. J Child Psychol Psychiatry; 2005 Feb;46(2):150-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Stroop revisited: a meta-analysis of interference control in AD/HD.
  • BACKGROUND: An inhibition deficit, including poor interference control, has been implicated as one of the core deficits in AD/HD.
  • The aim of this meta-analysis was to investigate the strength of an interference deficit in AD/HD as measured by the Stroop Colour-Word Task and to assess the role of moderating variables that could explain the results.
  • These moderating variables included: methods of calculating the interference score, comorbid reading and psychiatric disorders, AD/HD-subtypes, gender, age, intellectual functioning, medication, and sample size.
  • METHODS: Seventeen independent studies were located including 1395 children, adolescents, and young adults, in the age range of 6-27 years.
  • RESULTS: Children with AD/HD performed more poorly on all three dependent variables.
  • When interference control was calculated as the difference between the score on the colour card minus the score on the colour-word card, no differences were found between AD/HD groups and normal control groups.
  • DISCUSSION: The Stroop Colour-Word Task, in standard form, does not provide strong evidence for a deficit in interference control in AD/HD.
  • However, the Stroop Colour-Word Task may not be a valid measure of interference control in AD/HD and alternative methodologies may be needed to test this aspect of the inhibitory deficit model in AD/HD.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Psychological Tests. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679524.001).
  • [ISSN] 0021-9630
  • [Journal-full-title] Journal of child psychology and psychiatry, and allied disciplines
  • [ISO-abbreviation] J Child Psychol Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  •  go-up   go-down


51. Holt K: What do we tell the children? Contrasting the disclosure choices of two HD families regarding risk status and predictive genetic testing. J Genet Couns; 2006 Aug;15(4):253-65
MedlinePlus Health Information. consumer health - Huntington's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What do we tell the children? Contrasting the disclosure choices of two HD families regarding risk status and predictive genetic testing.
  • This study uses a phenomenological methodology to explore the contrasting choices of two sets of HD parents regarding the disclosure of genetic risk status to their children.
  • Additionally, the children (now adults) discuss their lived experience growing up with contrasting disclosure dynamics, and their current views regarding the use of predictive genetic testing for themselves.
  • The primary finding of this study is that all of the adult children now express preference for early disclosure of genetic risk and an open/supportive communication style regarding HD.
  • This finding has value for clinicians working with HD families who must make decisions regarding disclosure issues related to predictive genetic testing.
  • [MeSH-major] Choice Behavior. Genetic Counseling. Genetic Testing / psychology. Huntington Disease / genetics. Parents / psychology. Truth Disclosure
  • [MeSH-minor] Adaptation, Psychological. Adolescent. Adult. Attitude to Health. Awareness. Child. Communication. Concept Formation. Female. Humans. Male. Middle Aged. Parent-Child Relations

  • MedlinePlus Health Information. consumer health - Genetic Counseling.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychiatr Serv. 2002 Jun;53(6):703-5 [12045306.001]
  • [Cites] Fam Process. 2002 Winter;41(4):677-92 [12613124.001]
  • [Cites] Nurs Health Sci. 2004 Jun;6(2):123-30 [15130098.001]
  • [Cites] Psychooncology. 2004 May;13(5):335-45 [15133774.001]
  • [Cites] Lancet. 1993 Oct 16;342(8877):954-8 [8105214.001]
  • [Cites] Community Genet. 2004;7(1):25-32 [15475668.001]
  • [Cites] J Child Adolesc Psychiatr Nurs. 2003 Oct-Dec;16(4):162-75 [14748452.001]
  • [Cites] Obstet Gynecol Clin North Am. 2002 Jun;29(2):255-63, v [12108826.001]
  • [Cites] Eur J Hum Genet. 2000 Oct;8(10):731-8 [11039571.001]
  • [Cites] Eur J Hum Genet. 2002 Mar;10(3):167-76 [11973620.001]
  • [Cites] Community Genet. 2004;7(1):15-24 [15475667.001]
  • [Cites] Bioethics. 2001 Jun;15(3):231-47 [11700677.001]
  • [Cites] Psychooncology. 2000 Nov-Dec;9(6):522-7 [11180587.001]
  • [Cites] Fam Process. 2003 Spring;42(1):47-57 [12698598.001]
  • [Cites] Am J Med Genet. 2000 Jan 3;90(1):49-59 [10602118.001]
  • [Cites] J Health Psychol. 2002 Mar;7(2):125-30 [22114232.001]
  • [Cites] J Natl Cancer Inst Monogr. 1999;(25):59-66 [10854459.001]
  • [Cites] J Genet Couns. 2004 Apr;13(2):135-55 [15604629.001]
  • [Cites] Nurs Stand. 2004 Apr 21-27;18(32):45-51; quiz 52-3 [15132037.001]
  • [Cites] J Genet Couns. 2002 Oct;11(5):351-67 [12625340.001]
  • [Cites] Clin Genet. 2003 Oct;64(4):317-26 [12974737.001]
  • [Cites] J Clin Invest. 2003 Feb;111(3):299-302 [12569151.001]
  • (PMID = 16850280.001).
  • [ISSN] 1059-7700
  • [Journal-full-title] Journal of genetic counseling
  • [ISO-abbreviation] J Genet Couns
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Brocklebank D, Gayán J, Andresen JM, Roberts SA, Young AB, Snodgrass SR, Penney JB, Ramos-Arroyo MA, Cha JJ, Rosas HD, Hersch SM, Feigin A, Cherny SS, Wexler NS, Housman DE, Cardon LR, International-Venezuela Collaborative Research Group: Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications. Am J Med Genet B Neuropsychiatr Genet; 2009 Apr 5;150B(3):425-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications.
  • The instability of the CAG repeat size of the HD gene when transmitted intergenerationally has critical implications for genetic counseling practices.
  • To address this issue, we analyzed allelic instability in the Venezuelan HD kindreds, the largest and most informative families ascertained for HD.

  • MedlinePlus Health Information. consumer health - Family Issues.
  • MedlinePlus Health Information. consumer health - Genetic Counseling.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18712713.001).
  • [ISSN] 1552-485X
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY012562; United States / NINDS NIH HHS / NS / NS22031-15; United States / NEI NIH HHS / EY / EY-12562; United States / NINDS NIH HHS / NS / R01 NS022031-15; United States / NCI NIH HHS / CA / P01 CA042063-179001; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  • [Other-IDs] NLM/ NIHMS107831; NLM/ PMC4636008
  •  go-up   go-down


53. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC, Predict-HD Investigators of the Huntington Study Group: Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry; 2007 Dec 15;62(12):1341-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study.
  • BACKGROUND: Psychiatric disturbances are relatively common in manifest Huntington's disease (HD), but less is known about these symptoms in the earliest phase of the illness.
  • METHODS: This study examined self-reported psychiatric symptoms in a large sample (N = 681) of prediagnosed individuals who show the gene expansion for HD ("expansion-positive") compared with a sample of individuals who do not show the gene expansion but are at risk for HD ("expansion-negative").
  • RESULTS: Using baseline Symptom Checklist 90-Revised (SCL-90-R) data from the Predict-HD study, expansion-positive individuals reported significantly more psychiatric symptoms (e.g., depression, anxiety, obsessive-compulsiveness) than expansion-negative individuals.
  • The SCL-90-R scores had stronger relationships with reported abilities to perform activities of daily living than other markers of HD.
  • CONCLUSIONS: Subtle, subclinical psychiatric symptoms are present in this prediagnosed HD sample, even though most are estimated to be more than 10 years from HD diagnosis.
  • As suggested by other research, these subtle symptoms might be the earliest markers of the disease; however, longitudinal data are needed.
  • [MeSH-major] Behavioral Symptoms / physiopathology. Huntington Disease / diagnosis. Huntington Disease / physiopathology. Mental Disorders / physiopathology
  • [MeSH-minor] Adult. Cohort Studies. Disease Progression. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neuropsychological Tests. Predictive Value of Tests. Psychiatric Status Rating Scales

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481592.001).
  • [ISSN] 1873-2402
  • [Journal-full-title] Biological psychiatry
  • [ISO-abbreviation] Biol. Psychiatry
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / MH01579; United States / NINDS NIH HHS / NS / NS440068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Ilic M, Stokić E: Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern Med; 2007;46(13):945-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron.
  • OBJECTIVE: Insulin resistance and metabolic syndrome (MeS) are common in end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD).
  • Such metabolic and clinical abnormalities may lead to an increased risk for cardiovascular disease.
  • Logistical regression analysis was used to evaluate the correlation between measured variables and the presence of MeS in HD patients.
  • CONCLUSION: The present study demonstrated that serum iron participated together with independent predictors, glucose and BMI, in the pathogenesis of IR and MeS of ESRD patients on maintenance HD.
  • [MeSH-minor] Adult. Analysis of Variance. Blood Glucose / analysis. Body Composition. Body Mass Index. Cardiovascular Diseases / prevention & control. Case-Control Studies. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Inflammation / diagnosis. Inflammation / epidemiology. Logistic Models. Male. Middle Aged. Nutritional Status. Predictive Value of Tests. Risk Factors. Severity of Illness Index. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603231.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Blood Glucose; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins
  •  go-up   go-down


55. Gingras MC, Kharitidi D, Chénard V, Uetani N, Bouchard M, Tremblay ML, Pause A: Expression analysis and essential role of the putative tyrosine phosphatase His-domain-containing protein tyrosine phosphatase (HD-PTP). Int J Dev Biol; 2009;53(7):1069-74
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and essential role of the putative tyrosine phosphatase His-domain-containing protein tyrosine phosphatase (HD-PTP).
  • The putative tyrosine phosphatase HD-PTP, encoded by the protein-tyrosine-phosphatase-n23 (Ptpn23) gene, has been described as a tumor suppressor candidate gene.
  • To investigate HD-PTP functions, we generated a mouse model in which the Ptpn23 locus was disrupted by an in-frame insertion of a beta-galactosidase-neomycin-phosphotransferase II (beta-geo) cassette.
  • Our results show that Ptpn23 is expressed early during mouse development and that its expression is maintained in adult tissues, markedly in the epithelial cells of many organs.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378249.001).
  • [ISSN] 1696-3547
  • [Journal-full-title] The International journal of developmental biology
  • [ISO-abbreviation] Int. J. Dev. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; EC 3.1.3.48 / Protein Tyrosine Phosphatases, Non-Receptor
  •  go-up   go-down


56. Nunes S, Pereira I, Santos A, Bernardes R, Cunha-Vaz J: Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME. Br J Ophthalmol; 2010 Sep;94(9):1201-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME.
  • AIMS: To investigate the correlation between increased retinal thickness (RT) measured with spectral domain high-definition optical coherence tomography (OCT) (Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, California, USA)) and best-corrected visual acuity (BCVA) in eyes with clinically significant macular oedema (CSME) and type 2 diabetes.
  • Sixty-two eyes were considered for analysis and were classified as having/not having retinal thickening in the central fovea (central 500-microm-diameter circle) by Cirrus HD-OCT.
  • RESULTS: In the 19 eyes with CMSE identified by Cirrus HD-OCT without increased RT in the central fovea (500-microm-diameter circle), no correlation was found between RT and BCVA (R=0.062; 95% CI -0.404 to 0.502).
  • In the 43 eyes where the Cirrus HD-OCT identified an increased RT in the central fovea (central 500-microm-diameter circle), only a moderate correlation between RT and BCVA was found (R=-0.459; 95% CI -0.667 to -0.184).
  • [MeSH-minor] Adult. Aged. Female. Fluorescein Angiography. Fundus Oculi. Humans. Male. Middle Aged. Tomography, Optical Coherence / methods. Visual Acuity / physiology

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Diabetic Eye Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530184.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Leger D, Scheuermaier K, Raffray T, Metlaine A, Choudat D, Guilleminault C: HD-16: a new quality of life instrument specifically designed for insomnia. Sleep Med; 2005 May;6(3):191-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HD-16: a new quality of life instrument specifically designed for insomnia.
  • Based on the 16 items selected, we called the scale Hotel Dieu 16 (HD-16).
  • CONCLUSION: HD-16 may be used as a focused instrument to better assess an insomniac's quality of life.
  • [MeSH-minor] Adult. Female. Humans. Male. Reproducibility of Results. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Insomnia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854848.001).
  • [ISSN] 1389-9457
  • [Journal-full-title] Sleep medicine
  • [ISO-abbreviation] Sleep Med.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Vernoud V, Laigle G, Rozier F, Meeley RB, Perez P, Rogowsky PM: The HD-ZIP IV transcription factor OCL4 is necessary for trichome patterning and anther development in maize. Plant J; 2009 Sep;59(6):883-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HD-ZIP IV transcription factor OCL4 is necessary for trichome patterning and anther development in maize.
  • Among the genes controlling the differentiation and maintenance of epidermal cell fate are members of the HD-ZIP IV class family of plant-specific transcription factors, most of which are specifically expressed in the epidermis of tissues.
  • Here, we report the functional analysis of the maize HD-ZIP IV gene OCL4 (outer cell layer 4) via the phenotypic analysis of two insertional mutants, and of OCL4-RNAi transgenic plants.
  • In all three materials, the macrohairs, one of the three types of trichomes present on adult maize leaf blades, developed ectopically at the margin of juvenile and adult leaves.
  • Expression of OCL4 in the model plant Arabidopsis under the control of the GLABRA2 (GL2) promoter, a member of the Arabidopsis HD-ZIP IV family involved in trichome differentiation, did not complement the gl2-1 mutant, but instead aggravated its phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453441.001).
  • [ISSN] 1365-313X
  • [Journal-full-title] The Plant journal : for cell and molecular biology
  • [ISO-abbreviation] Plant J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Plant Proteins; 0 / RNA, Plant; 0 / Transcription Factors
  •  go-up   go-down


59. Kang SH, Hong SW, Im SK, Lee SH, Ahn MD: Effect of myopia on the thickness of the retinal nerve fiber layer measured by Cirrus HD optical coherence tomography. Invest Ophthalmol Vis Sci; 2010 Aug;51(8):4075-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of myopia on the thickness of the retinal nerve fiber layer measured by Cirrus HD optical coherence tomography.
  • PURPOSE: To evaluate the effect of myopia on the peripapillary retinal nerve fiber layer (RNFL) thickness measured by Cirrus HD optical coherence tomography (OCT).
  • Further, 200 x 200-cube optic disc scans of the subjects' eyes were obtained with Cirrus HD OCT.
  • [MeSH-minor] Adult. Female. Glaucoma / diagnosis. Humans. Male. Refraction, Ocular. Tomography, Optical Coherence. Visual Acuity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20237247.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Xu EH, Tang Y, Li D, Jia JP: Polymorphism of HD and UCHL-1 genes in Huntington's disease. J Clin Neurosci; 2009 Nov;16(11):1473-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism of HD and UCHL-1 genes in Huntington's disease.
  • This study analyzed the association between the polymorphism of the Huntington's disease (HD) and ubiquitin carboxyl-terminal hydrolase L1 (UCHL-1) genes and the age of HD onset.
  • We examined the size of trinucleotide CAG repeats in the HD gene of 53 individuals from families with a history of HD, six unrelated HD patients, and 51 healthy controls.
  • We identified five HD patients in the families and four pre-clinical HD patients in their high-risk offspring.
  • The YY genotype was not identified in non-related HD patients, and the SS genotype had a higher prevalence than the SY genotype.
  • Multiple linear regression analysis revealed that UCHL-1 S18Y polymorphism accounted for 15.6% of variance in the age of disease onset among 11 patients.
  • The size of CAG repeats in the HD gene is an important factor affecting the age at disease onset, but is not the only factor.
  • UCHL-1 S18Y polymorphism is a modifier of HD with a modest regulatory role in the age at disease onset, suggesting that UCHL-1 may be involved in HD pathogenesis.
  • [MeSH-major] Huntington Disease / genetics. Polymorphism, Genetic / genetics. Trinucleotide Repeat Expansion / genetics. Ubiquitin Thiolesterase / genetics
  • [MeSH-minor] Adult. Age of Onset. Aged. Alleles. Chi-Square Distribution. Family Health. Female. Gene Frequency. Genotype. Humans. Male. Middle Aged. Serine / genetics. Tyrosine / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19683447.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 42HK56048U / Tyrosine; 452VLY9402 / Serine; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


61. Tomlins PJ, Woodcock MG, Spencer N, Kirkby GR: Nuclear magnetic resonance analysis of emulsified silicone oil RMN-3 (Oxane HD). Br J Ophthalmol; 2007 Oct;91(10):1379-81
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear magnetic resonance analysis of emulsified silicone oil RMN-3 (Oxane HD).
  • BACKGROUND: Oxane HD is a mixture of 5700 cs silicone oil and RMN-3 (a partly fluorinated olefin), which has a specific gravity greater than water, thereby enabling endotamponade of inferior retinal breaks.
  • Droplets of emulsified oil were found in the anterior chamber of two patients with complex retinal detachments who had been treated with Oxane HD.
  • Samples taken from different areas of an unused syringe of Oxane HD demonstrated varying concentrations of the RMN-3 compound within the silicone oil.
  • [MeSH-minor] Adult. Anterior Chamber. Emulsions / chemistry. Humans. Male. Middle Aged. Pseudophakia / surgery. Silicone Oils / chemistry. Vitrectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Retina. 2003 Jun;23(3):335-42 [12824833.001]
  • [Cites] Br J Ophthalmol. 2004 May;88(5):692-6 [15090425.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1153-7 [15983817.001]
  • [Cites] Br J Ophthalmol. 2005 Jun;89(6):662-5 [15923496.001]
  • [Cites] Retina. 2005 Apr-May;25(3):332-8 [15805911.001]
  • (PMID = 17431021.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Emulsions; 0 / Silicone Oils
  • [Other-IDs] NLM/ PMC2001015
  •  go-up   go-down


62. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD investigators: Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol; 2009 Sep;8(9):791-801
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
  • BACKGROUND: Huntington's disease (HD) is an autosomal dominant, fully penetrant, neurodegenerative disease that most commonly affects adults in mid-life.
  • Our aim was to identify sensitive and reliable biomarkers in premanifest carriers of mutated HTT and in individuals with early HD that could provide essential methodology for the assessment of therapeutic interventions.
  • Blinded analyses were done on the baseline cross-sectional data from 366 individuals: 123 controls, 120 premanifest (pre-HD) individuals, and 123 patients with early HD.
  • Cross-sectional analyses identified significant changes in whole-brain volume, regional grey and white matter differences, impairment in a range of voluntary neurophysiological motor, and oculomotor tasks, and cognitive and neuropsychiatric dysfunction in premanifest HD gene carriers with normal motor scores through to early clinical stage 2 disease.
  • Many parameters differ from age-matched controls in a graded fashion and show changes of increasing magnitude across our cohort, who range from about 16 years from predicted disease diagnosis to early HD.
  • [MeSH-major] Biomarkers / analysis. Brain / physiopathology. Huntington Disease / diagnosis. Huntington Disease / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Atrophy / diagnosis. Atrophy / pathology. Atrophy / physiopathology. Cognition Disorders / diagnosis. Cognition Disorders / etiology. Cognition Disorders / physiopathology. Cohort Studies. Cross-Sectional Studies. Disease Progression. Early Diagnosis. Female. Genetic Predisposition to Disease / genetics. Genetic Testing. Heterozygote Detection / methods. Humans. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination / methods. Predictive Value of Tests. Reference Values. Young Adult

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mov Disord. 2008 Jun 15;23(8):1100-7 [18412252.001]
  • [Cites] Neurology. 2004 Jul 13;63(1):66-72 [15249612.001]
  • [Cites] Prog Brain Res. 2008;171:555-8 [18718352.001]
  • [Cites] Mov Disord. 2009 Apr 30;24(6):932-6 [19243073.001]
  • [Cites] Comput Med Imaging Graph. 2002 Jul-Aug;26(4):251-64 [12074920.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):452-8 [10668713.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):544-9 [10676962.001]
  • [Cites] Clin Genet. 2004 Apr;65(4):267-77 [15025718.001]
  • [Cites] Nat Rev Neurosci. 2004 Mar;5(3):218-28 [14976521.001]
  • [Cites] Neurology. 1979 Jan;29(1):1-3 [154626.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Ann Neurol. 1996 Jul;40(1):49-54 [8687191.001]
  • [Cites] Comput Methods Programs Biomed. 1997 May;53(1):15-25 [9113464.001]
  • [Cites] Ann Neurol. 1997 May;41(5):689-92 [9153534.001]
  • [Cites] Neurology. 1999 Sep 11;53(4):806-12 [10489045.001]
  • [Cites] Neurology. 2005 Sep 13;65(5):745-7 [16157910.001]
  • [Cites] Biol Psychiatry. 2006 Jan 1;59(1):57-63 [16112655.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):215-22 [16455626.001]
  • [Cites] Arch Neurol. 2006 Jun;63(6):883-90 [16769871.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):485-7 [16625001.001]
  • [Cites] Brain. 2007 Jul;130(Pt 7):1732-44 [17584778.001]
  • [Cites] J Int Neuropsychol Soc. 2007 Sep;13(5):758-69 [17697407.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):939-43 [17178819.001]
  • [Cites] Brain. 2007 Nov;130(Pt 11):2845-57 [17855375.001]
  • [Cites] Brain. 2008 Jan;131(Pt 1):196-204 [18056161.001]
  • [Cites] Neuropsychologia. 2008;46(8):2152-60 [18407301.001]
  • [Cites] Cell. 2000 Mar 31;101(1):57-66 [10778856.001]
  • [Cites] Exp Neurol. 2000 May;163(1):136-48 [10785452.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Dec;69(6):773-9 [11080230.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Jan;20(1):70-80 [11293693.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):219-26 [11725215.001]
  • [Cites] Neurology. 2002 Mar 12;58(5):695-701 [11889230.001]
  • [Cites] Acta Psychiatr Scand. 2002 Mar;105(3):224-30 [11939977.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1815-28 [12135972.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80 [18096682.001]
  • (PMID = 19646924.001).
  • [ISSN] 1474-4422
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS042861-04; United States / NINDS NIH HHS / NS / P01 NS058793; United States / NCRR NIH HHS / RR / M01 RR001066-305062; United States / NINDS NIH HHS / NS / R01 NS042861; United States / NINDS NIH HHS / NS / P01 NS058793-02; United States / NCRR NIH HHS / RR / M01 RR001066; United States / NINDS NIH HHS / NS / P01 NS058793-01A10001; United Kingdom / Medical Research Council / / G0601846; United States / NINDS NIH HHS / NS / R01 NS042861-05
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS173425; NLM/ PMC3725974
  • [Investigator] Coleman A; Dar Santos R; Decolongon J; Sturrock A; Bardinet E; Jauffret C; Justo D; Lehericy S; Marelli C; Nigaud K; Valabrègue R; Bechtel N; Hoffman A; Kraus P; van den Bogaard SJ; Dumas EM; van der Grond J; t'Hart EP; Jurgens C; Witjes-Ane MN; Arran N; Frost C; Jones R; Hobbs N; Lahiri N; Ordidge R; Owen G; Pepple T; Read J; Say M; Wild E; Keenan S; Cash DM; Axelson E; Wang C; Lee S; Monaco W; Campbell C; Queller S; Whitlock K; Campbell C; Campbell M; Frajman E; Michman C; O'Regan A
  •  go-up   go-down


63. Nichols R, Hopman WM, Morton AR, Harman GJ, Holden RM: Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients. Hemodial Int; 2008 Apr;12(2):275-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients.
  • The Dialysis Outcomes and Practice Patterns Study reported a statistically non-significant protective effect of HMG-co reductase inhibitors (statins) on bone fracture risk in hemodialysis (HD) patients.
  • We sought to determine whether statin exposure was associated with reduced risk of bone fracture in our HD population.
  • This was a retrospective cohort study of 174 prevalent HD patients.
  • The subjects were 174 HD patients (68.4% male) with a median age of 69.1 and age range from 25.2 to 96.3 years.
  • The median age at initiation of HD was 62.5, ranging from 15.2 to 90.5 years.
  • Logistic regression analysis (stepwise, alpha=0.05) was performed with dependent variable bone fracture and independent variables age at HD initiation (forced), dialysis vintage, gender (forced), prednisone use (forced), and statin exposure.
  • The significant predictors of bone fracture (R2=0.14, p=0.004) were age at HD initiation (p=0.016), dialysis vintage (p=0.007), and absence of statin exposure (p=0.019).
  • Statin exposure appears to be associated with a reduced frequency of bone fracture in HD patients.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394063.001).
  • [ISSN] 1492-7535
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


64. Williams JK, Erwin C, Juhl AR, Mengeling M, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS, I-RESPOND-HD Investigators of the Huntington Study Group: In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet; 2010 Sep;153B(6):1150-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study.
  • Genetic discrimination may be experienced in the day-to-day lives of people at risk for Huntington disease (HD), encompassing occurrences in the workplace, when seeking insurance, within social relationships, and during other daily encounters.
  • At-risk individuals who have tested either positive or negative for the genetic expansion that causes HD, as well as at-risk persons with a 50% chance for developing the disorder but have not had DNA testing completed the International RESPOND-HD (I-RESPOND-HD) survey.

  • Genetic Alliance. consumer health - Huntington disease.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Res Nurs Health. 2000 Aug;23(4):334-40 [10940958.001]
  • [Cites] BMJ. 2009;338:b2175 [19509425.001]
  • [Cites] Genet Med. 2001 Sep-Oct;3(5):354-8 [11545689.001]
  • [Cites] J Adv Nurs. 2003 Apr;42(1):57-63 [12641812.001]
  • [Cites] J Health Care Law Policy. 2000;3(2):225-65 [15015481.001]
  • [Cites] West J Nurs Res. 1988 Apr;10(2):195-218 [3394320.001]
  • [Cites] Community Genet. 2004;7(4):161-8 [15692189.001]
  • [Cites] Int Psychogeriatr. 2005;17 Suppl 1:S223-31 [16240492.001]
  • [Cites] Arch Neurol. 2006 Jun;63(6):883-90 [16769871.001]
  • [Cites] Arch Neurol. 2006 Jul;63(7):991-6 [16831969.001]
  • [Cites] Clin Genet. 2007 Mar;71(3):220-31 [17309644.001]
  • [Cites] Eur J Hum Genet. 2008 Mar;16(3):279-89 [17957229.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):320-5 [17948904.001]
  • [Cites] Clin Genet. 2008 Jul;74(1):20-30 [18492091.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80 [18096682.001]
  • [Cites] Am J Med Genet A. 2008 Aug 15;146A(16):2070-7 [18627059.001]
  • [Cites] J Clin Psychiatry. 2008 Nov;69(11):1758-65 [19012814.001]
  • [Cites] J Adv Nurs. 2009 Apr;65(4):789-98 [19228233.001]
  • [Cites] Genet Med. 2009 Mar;11(3):193-201 [19287242.001]
  • [Cites] Neurology. 2001 Aug 28;57(4):658-62 [11524475.001]
  • (PMID = 20468062.001).
  • [ISSN] 1552-485X
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS040068; United States / NINDS NIH HHS / NS / NS40068; United States / NINDS NIH HHS / NS / R01 NS040068-10; United States / NHGRI NIH HHS / HG / HG003330-01A1; United States / NHGRI NIH HHS / HG / R01 HG003330-01A1; United States / NHGRI NIH HHS / HG / R01 HG003330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS262331; NLM/ PMC3035936
  • [Investigator] Adams W; Elbert M; Paulsen J; Williams J; Chiu E; Goh A; Yastrubetskaya O; Agarwal A; Rosenblatt A; Welsh C; Marder K; Wasserman P; Moskowitz C; Decolongon J; Raymond LA; Lipe H; Samii A; Williams P; Aylward E; Harrison JM; Jones R; Wood-Siverio C; Quaid K; Wesson M; Biglan K; Chesire A; Como P; Giambattista C; Guttman M; Sheinberg A; Singer A; Griffith J; McCusker E; Richardson K; Tempkin T; Wheelock VL; Johnson A; Linderholm W; Perlman S; Geschwind MD; Gooblar J; Guzijan M; Chua P; Komiti A; Panegyres P; Vuletich E; Woodman M
  •  go-up   go-down


65. Bhanushali AA, Babu S, Thangapandi VR, Pillai R, Chheda P, Das BR: Mutations in the HD and PEST domain of Notch-1 receptor in T-cell acute lymphoblastic leukemia: report of novel mutations from Indian population. Oncol Res; 2010;19(2):99-104
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the HD and PEST domain of Notch-1 receptor in T-cell acute lymphoblastic leukemia: report of novel mutations from Indian population.
  • The current study was undertaken to characterize mutations in the heterodimerization (HD) domain and proline, glutamic acid, serine, threonine-rich (PEST) domain of the Notch-1 receptor.
  • RNA was isolated from peripheral blood/bone marrow of 15 de novo T-ALL subjects; the Notch-1 HD and PEST regions were amplified and sequenced.
  • Overall six patients (40%) had at least one Notch-1 mutation, 2/15 (13%) in the HD and 4/15 (27%) in the PEST domain.
  • None of the samples showed simultaneous mutations in HD and PEST domains.
  • Mutations were seen in 4/10 adult patients (40%); in the pediatric cohort 2/5 (40%) had mutations both of which were in the PEST domain.
  • [MeSH-major] Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Adult. Base Sequence. Child. Humans. India. Protein Multimerization. Protein Structure, Tertiary. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302811.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Notch1
  •  go-up   go-down


66. Ducreux M, Raoul JL, Marti P, Merrouche Y, Tigaud JM, Rebischung C, Boige V: High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology; 2008;74(1-2):17-24
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
  • This study aimed to determine the safety and efficacy of high-dose (HD) irinotecan combined with LV5FU2 or simplified LV5FU (LV5FUs) in first-line treatment of metastatic colorectal cancer.
  • PATIENTS AND METHODS: Patients with unresectable and measurable metastatic colorectal cancer, not pretreated for metastatic disease, were given irinotecan 260 mg/m(2) combined with LV5FU2 in the first 25 patients, then with LV5FUs (HD-FOLFIRI) in 35 patients.
  • CONCLUSION: HD-irinotecan plus LV5FU2 or HD-FOLFIRI is feasible and achieved a high response rate and postsurgery complete response rate.
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoadjuvant Therapy. Survival Analysis. Treatment Outcome


67. Kar P, Asim M, Sarma MP, Patki PS: HD-03/ES: a promising herbal drug for HBV antiviral therapy. Antiviral Res; 2009 Dec;84(3):249-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HD-03/ES: a promising herbal drug for HBV antiviral therapy.
  • INTRODUCTION: The present study was designed to study the genotypes associated with different groups of chronic liver disease and to see their response to HD-03/ES (an antiviral herbal molecule) on chronic HBV patients.
  • METHODS: A total of 51 patients of chronic liver disease were recruited in the study and were given HD-03/ES, two capsules twice daily for 6 months.
  • RESULTS: After 6 months of therapy with HD-03/ES, a significant reduction of ALT values from 71.2 + or - 16.3 to 36.4 + or - 6.8 and a significant HBeAg loss (27.4%) and HBV DNA loss (27.4%) was observed.
  • CONCLUSION: The study had shown that majority of the patients of chronic HBV related liver disease had genotype D.
  • [MeSH-minor] Adolescent. Adult. DNA, Viral / blood. DNA, Viral / genetics. Drug Administration Schedule. Genotype. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19800917.001).
  • [ISSN] 1872-9096
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / HD 03 polyherbal; 0 / Plant Extracts
  •  go-up   go-down


68. Lafosse JM, Corboy JR, Leehey MA, Seeberger LC, Filley CM: MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically? J Clin Exp Neuropsychol; 2007 Feb;29(2):142-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically?
  • Nineteen patients with multiple sclerosis (MS), 16 with Huntington's disease (HD), and 17 normal controls (NC) participated.
  • The principal findings pertain to a dissociation in procedural memory: on RP, the HD group demonstrated impaired sequence learning compared to the MS group, which performed similarly to the NC group, yet on MT, the MS and HD groups demonstrated normal perceptual-motor integration learning.
  • On the SDMT, both patient groups performed worse than the NC group, with the HD group performing more poorly than the MS and NC groups.
  • [MeSH-major] Brain / pathology. Huntington Disease / pathology. Huntington Disease / psychology. Multiple Sclerosis / pathology. Multiple Sclerosis / psychology. Neuropsychological Tests
  • [MeSH-minor] Adult. Aging / pathology. Aging / psychology. Association Learning / physiology. Education. Female. Humans. Male. Middle Aged. Motor Skills / physiology. Sex Characteristics. Verbal Learning / physiology

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365249.001).
  • [ISSN] 1380-3395
  • [Journal-full-title] Journal of clinical and experimental neuropsychology
  • [ISO-abbreviation] J Clin Exp Neuropsychol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carbone C, Quattrin S, Fioritoni G, D'Alfonso G, Mandelli F, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party: Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood; 2007 Feb 15;109(4):1401-7
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.
  • Recently, a single high-dose dexamethasone (HD-DXM) course was administered as first-line therapy in adult patients with ITP.
  • In this paper we show the results of 2 prospective pilot studies (monocentric and multicentric, respectively) concerning the use of repeated pulses of HD-DXM in untreated ITP patients.
  • HD-DXM was given in 4-day pulses every 28 days, for 6 cycles.
  • HD-DXM was given in 4-day pulses every 14 days, for 4 cycles; 90 patients completed 4 cycles.
  • A schedule of 3 cycles of HD-DXM pulses will be compared with standard prednisone therapy (eg, 1 mg/kg per day) in the next randomized Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) trial.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infant. Male. Middle Aged. Pilot Projects. Prospective Studies. Remission Induction


70. Frank S: Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol; 2009 Dec 18;9:62
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.
  • A previous double blind study in Huntington disease (HD) demonstrated that TBZ effectively suppressed chorea, with a favorable short-term safety profile (Neurology 2006;66:366-372).
  • The objective of this study was to assess the long-term safety and effectiveness of TBZ for chorea in HD.
  • Chorea was assessed using the Total Maximal Chorea (TMC) score from the Unified Huntington Disease Rating Scale.
  • CONCLUSIONS: TBZ effectively suppresses HD-related chorea for up to 80 weeks.
  • [MeSH-major] Adrenergic Uptake Inhibitors / therapeutic use. Huntington Disease / drug therapy. Tetrabenazine / therapeutic use
  • [MeSH-minor] Adult. Aged. Disability Evaluation. Double-Blind Method. Drug Evaluation / methods. Follow-Up Studies. Humans. Middle Aged. Severity of Illness Index. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Huntington disease.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):550 [10610387.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):397-404 [11502903.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):694-9 [12221159.001]
  • [Cites] Clin Neuropharmacol. 2002 Nov-Dec;25(6):300-2 [12469001.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jan;80(2):584-8 [6572908.001]
  • [Cites] Biochem Pharmacol. 1983 Oct 1;32(19):2851-6 [6626259.001]
  • [Cites] Mol Pharmacol. 1984 Jan;25(1):113-22 [6708929.001]
  • [Cites] Eur J Pharmacol. 1984 Jul 20;102(3-4):431-6 [6149131.001]
  • [Cites] Am J Med Genet. 1986 Jun;24(2):305-11 [2940862.001]
  • [Cites] J Pharm Sci. 1987 Jun;76(6):461-5 [3625491.001]
  • [Cites] Br J Psychiatry. 1989 May;154:672-6 [2574607.001]
  • [Cites] J Med Genet. 1993 Apr;30(4):293-5 [8487273.001]
  • [Cites] Mov Disord. 1995 Jan;10(1):103-5 [7885343.001]
  • [Cites] Brain Res. 1995 Sep 18;692(1-2):233-43 [8548309.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Neurology. 1997 Feb;48(2):358-62 [9040721.001]
  • [Cites] Neurology. 1998 May;50(5):1366-73 [9595988.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62 [14399272.001]
  • [Cites] Am J Psychiatry. 2005 Apr;162(4):725-31 [15800145.001]
  • [Cites] Neurology. 2006 Feb 14;66(3):366-72 [16476934.001]
  • [Cites] Curr Pharm Des. 2006;12(21):2701-20 [16842168.001]
  • [Cites] Clin Neuropharmacol. 2006 Sep-Oct;29(5):259-64 [16960470.001]
  • [Cites] Mov Disord. 2007 Jan;22(1):10-3 [17078062.001]
  • [Cites] Mov Disord. 2007 Jan 15;22(2):193-7 [17133512.001]
  • [Cites] J Neurosci. 2007 Jul 25;27(30):7899-910 [17652581.001]
  • [Cites] Neurotherapeutics. 2008 Apr;5(2):181-97 [18394562.001]
  • [Cites] Clin Neuropharmacol. 2008 May-Jun;31(3):127-33 [18520979.001]
  • [Cites] Curr Opin Neurol. 2008 Aug;21(4):497-503 [18607213.001]
  • [Cites] Mov Disord. 2008 Aug 15;23(11):1491-504 [18581443.001]
  • [Cites] Clin Neuropharmacol. 2008 Nov-Dec;31(6):313-8 [19050408.001]
  • [ErratumIn] BMC Neurol. 2011;11:18
  • (PMID = 20021666.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00219804
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; Z9O08YRN8O / Tetrabenazine
  • [Other-IDs] NLM/ PMC2804668
  •  go-up   go-down


71. McGreevy K, Lefkowitz D, Valiante D, Lipsitz S: Utilizing hospital discharge data (HD) to compare fatal and non-fatal work-related injuries among Hispanic workers in New Jersey. Am J Ind Med; 2010 Feb;53(2):146-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilizing hospital discharge data (HD) to compare fatal and non-fatal work-related injuries among Hispanic workers in New Jersey.
  • BACKGROUND: This study explores the utilization of Hospital Discharge (HD) data to obtain estimates of work-related non-fatal injuries rates in NJ to determine if Hispanics workers have an increased risk of specific work-related injuries.
  • In addition, HD data are used to compare the rate ratios between fatal and non-fatal injuries in this population to demonstrate the effectiveness of using HD as a surveillance tool for monitoring injury trends and performing evaluations.
  • CONCLUSIONS: HD data are effective for monitoring trends over time across ethnic groups and injury types.
  • [MeSH-minor] Adult. Age Distribution. Data Mining. Female. Humans. Male. Middle Aged. New Jersey / epidemiology. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19753614.001).
  • [ISSN] 1097-0274
  • [Journal-full-title] American journal of industrial medicine
  • [ISO-abbreviation] Am. J. Ind. Med.
  • [Language] eng
  • [Grant] United States / NIOSH CDC HHS / OH / 1U60 OH0345
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


72. Wickham L, Tranos P, Hiscott P, Charteris D: The use of silicone oil-RMN3 (Oxane HD) as heavier-than-water internal tamponade in complicated inferior retinal detachment surgery. Graefes Arch Clin Exp Ophthalmol; 2010 Sep;248(9):1225-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of silicone oil-RMN3 (Oxane HD) as heavier-than-water internal tamponade in complicated inferior retinal detachment surgery.
  • In this study we evaluated the efficacy of Oxane HD in the management of complex retinal detachments involving lower quadrants of the retina.
  • In those patients who re-detached under heavy silicone oil (n = 4), retro-oil epiretinal membranes (ERMs) were obtained at the time of subsequent surgery to analyse the immunopathological response to oxane HD.
  • CONCLUSION: We failed to observe an advantage following the use of Oxane HD in the treatment of inferior retinal detachments.
  • Moreover, Oxane HD was difficult to remove and was associated with a higher incidence of complications.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Epiretinal Membrane / metabolism. Epiretinal Membrane / pathology. Humans. Immunohistochemistry. Intraocular Pressure. Laser Coagulation. Lasers, Excimer. Macrophages / pathology. Middle Aged. Neuroglia / pathology. Prospective Studies. Retinal Perforations / surgery. Retinal Pigment Epithelium / pathology. Tonometry, Ocular. Treatment Outcome. Visual Acuity. Vitrectomy. Vitreoretinopathy, Proliferative / surgery

  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Graefes Arch Clin Exp Ophthalmol. 2011 Jun;249(6):949; author reply 951-2 [20737159.001]
  • [Cites] Br J Ophthalmol. 1987 Apr;71(4):262-7 [2437955.001]
  • [Cites] Ophthalmology. 1988 May;95(5):583-91 [3174019.001]
  • [Cites] Arch Ophthalmol. 1997 Mar;115(3):335-44 [9076205.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1986;224(1):34-7 [3943733.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):609-19 [16205937.001]
  • [Cites] Retina. 2004 Aug;24(4):567-73 [15300078.001]
  • [Cites] Retina. 1986 Spring-Summer;6(2):77-80 [3749624.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):965-71 [12483317.001]
  • [Cites] Ophthalmology. 1998 Sep;105(9):1587-97 [9754162.001]
  • [Cites] Eye (Lond). 2008 Oct;22(10):1342-59 [18344952.001]
  • [Cites] Br J Ophthalmol. 1994 Mar;78(3):219-22 [7511932.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Jul;242(7):617-20 [15029505.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):989-95 [12483321.001]
  • [Cites] Aust N Z J Ophthalmol. 1998 Nov;26(4):299-304 [9843257.001]
  • [Cites] Br J Ophthalmol. 2007 Feb;91(2):258-62 [17005544.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1439-42 [15489490.001]
  • [Cites] Br J Ophthalmol. 2001 Feb;85(2):179-83 [11159482.001]
  • [Cites] Retina. 2003 Jun;23(3):335-42 [12824833.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1994 Jul;232(7):438-44 [7926877.001]
  • [Cites] Br J Ophthalmol. 2004 May;88(5):692-6 [15090425.001]
  • [Cites] Ophthalmologe. 1996 Apr;93(2):121-5 [8652975.001]
  • [Cites] Am J Ophthalmol. 1991 Aug 15;112(2):159-65 [1867299.001]
  • [Cites] Retina. 1986 Summer-Fall;6(3):176-8 [3797834.001]
  • [Cites] Ophthalmology. 1992 Sep;99(9):1364-7 [1407970.001]
  • (PMID = 20349080.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Silicone Oils; 0 / oxane HD
  •  go-up   go-down


73. Park SB, Sung KR, Kang SY, Kim KR, Kook MS: Comparison of glaucoma diagnostic Capabilities of Cirrus HD and Stratus optical coherence tomography. Arch Ophthalmol; 2009 Dec;127(12):1603-9
MedlinePlus Health Information. consumer health - Optic Nerve Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of glaucoma diagnostic Capabilities of Cirrus HD and Stratus optical coherence tomography.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Female. Humans. Intraocular Pressure. Likelihood Functions. Male. Middle Aged. Prospective Studies. ROC Curve. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Glaucoma.
  • MedlinePlus Health Information. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008715.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Piske RL, Kanashiro LH, Paschoal E, Agner C, Lima SS, Aguiar PH: Evaluation of Onyx HD-500 embolic system in the treatment of 84 wide-neck intracranial aneurysms. Neurosurgery; 2009 May;64(5):E865-75; discussion E875
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Onyx HD-500 embolic system in the treatment of 84 wide-neck intracranial aneurysms.
  • OBJECTIVE: We report our results using Onyx HD-500 (Micro Therapeutics, Inc., Irvine, CA) in the endovascular treatment of wide-neck intracranial aneurysms, which have a high rate of incomplete occlusion and recanalization with platinum coils.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Confidence Intervals. Female. Follow-Up Studies. Humans. Imaging, Three-Dimensional / methods. Kaplan-Meier Estimate. Magnetic Resonance Angiography. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404128.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Onyx HD 500; 0 / Polyvinyls; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


75. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L: Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology; 2007 Apr;12(2):141-7
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
  • We have evaluated the best method to assess the ovarian reserve and the ovarian protective effect of GnRH-analog (GnRH-a), in 29 women with Hodgkin's disease (HD) treated with chemotherapy (CHT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / drug therapy. Infertility, Female / physiopathology. Ovarian Follicle / ultrasonography. Ovary / physiopathology. Primary Ovarian Insufficiency / physiopathology. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Amenorrhea / blood. Amenorrhea / chemically induced. Amenorrhea / physiopathology. Amenorrhea / prevention & control. Anti-Mullerian Hormone. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follicle Stimulating Hormone / blood. Glycoproteins / blood. Humans. Inhibins / blood. Luteinizing Hormone / blood. Mechlorethamine / administration & dosage. Mechlorethamine / adverse effects. Predictive Value of Tests. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Sensitivity and Specificity. Survivors. Testicular Hormones / blood. Time Factors. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454195.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Testicular Hormones; 0 / inhibin B; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 57285-09-3 / Inhibins; 57773-63-4 / Triptorelin Pamoate; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 80497-65-0 / Anti-Mullerian Hormone; 8N3DW7272P / Cyclophosphamide; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9PHQ9Y1OLM / Prednisolone; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; ABVD protocol; CMOPP protocol; DHAP protocol; MOPP protocol; MOPP-ABV protocol
  •  go-up   go-down


76. Savini G, Carbonelli M, Barboni P: Retinal nerve fiber layer thickness measurement by Fourier-domain optical coherence tomography: a comparison between cirrus-HD OCT and RTVue in healthy eyes. J Glaucoma; 2010 Aug;19(6):369-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal nerve fiber layer thickness measurement by Fourier-domain optical coherence tomography: a comparison between cirrus-HD OCT and RTVue in healthy eyes.
  • PURPOSE: To compare retinal nerve fiber layer (RNFL) thickness measurements by 2 Fourier-domain optical coherence tomography (OCT) instruments: Cirrus-HD OCT and RTVue.
  • The NMH4 and Optic Disk Cube 200x200 protocols were used, respectively, for scan acquisition with RTVue and Cirrus-HD OCT.
  • RESULTS: RTVue gave higher mean RNFL thickness values than Cirrus-HD OCT in the superior (128.44+/-22.48 vs. 119.73+/-18.22 mu, P=0.0002), inferior (137.15+/-21.99 vs. 124.94+/-22.51 mu, P<0.0001), nasal (77.58+/-15.61 vs. 70.21+/-11.53 mu, P=0.0009), and temporal (78.09+/-10.05 vs. 67.08+/-9.60 mu, P<0.0001) quadrants, as well as a higher 360 degrees average measurement (105.88+/-14.59 vs. 95.21+/-12.45 mu, P<0.0001).
  • CONCLUSIONS: In healthy eyes RNFL measurements taken with RTVue and Cirrus-HD OCT show significant differences that make the measurements themselves noninterchangeable.
  • [MeSH-minor] Adult. Aged. Algorithms. Anthropometry. Female. Fourier Analysis. Humans. Male. Middle Aged. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855291.001).
  • [ISSN] 1536-481X
  • [Journal-full-title] Journal of glaucoma
  • [ISO-abbreviation] J. Glaucoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Wild-Wall N, Oades RD, Juran SA: Maturation processes in automatic change detection as revealed by event-related brain potentials and dipole source localization: significance for adult AD/HD. Int J Psychophysiol; 2005 Oct;58(1):34-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maturation processes in automatic change detection as revealed by event-related brain potentials and dipole source localization: significance for adult AD/HD.
  • The bilateral scalp distribution develops by 14 years of age, and is elicited with adult latencies by 17 years.
  • But both temporal lobe sources were located significantly more ventrally and further left in the young adult than in the adolescent subjects.
  • [MeSH-minor] Adolescent. Adult. Discrimination (Psychology). Female. Functional Laterality / physiology. Humans. Male. Scalp

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922470.001).
  • [ISSN] 0167-8760
  • [Journal-full-title] International journal of psychophysiology : official journal of the International Organization of Psychophysiology
  • [ISO-abbreviation] Int J Psychophysiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Rajkumar JS, Sekar MG, Mitra SK: Safety and efficacy of oral HD-03/ES given for six months in patients with chronic hepatitis B virus infection. World J Gastroenterol; 2007 Aug 14;13(30):4103-7
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of oral HD-03/ES given for six months in patients with chronic hepatitis B virus infection.
  • AIM: To investigate the safety and efficacy of the formulation HD-03/ES capsules in the management of patients with chronic hepatitis B infection.
  • METHODS: A total of 25 patients were recruited to the study and were given HD-03/ES, two capsules twice daily for six months.
  • RESULTS: After 6 mo of therapy with HD-03/ES, a significant reduction of ALT values from 66.5 +/- 11.1 to 39.1 +/- 5.2 (P < 0.01) and a significant HBsAg loss (52%, P < 0.001), HBeAg loss (60%, P < 0.05) and HBV DNA loss (60%, P < 0.05) was observed.
  • CONCLUSION: The results of this pilot study indicate that HD-03/ES might be a safe and effective treatment for chronic hepatitis B infection and a long-term multicentric comparator trial is warranted and under way.
  • [MeSH-minor] Administration, Oral. Adult. Alanine Transaminase / metabolism. DNA, Viral / blood. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hepatitis B e Antigens / blood. Hepatitis B virus / genetics. Hepatitis B virus / immunology. Humans. Liver / drug effects. Liver / enzymology. Liver / virology. Male. Middle Aged. Pilot Projects. Prospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696230.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / HD 03 polyherbal; 0 / Hepatitis B e Antigens; 0 / Plant Extracts; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC4205313
  •  go-up   go-down


79. Powell S, Dudek AZ: Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res; 2009 Oct;29(10):4189-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
  • BACKGROUND: High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma.
  • The purpose of this study was to evaluate the response of metastatic melanoma to treatment with HD IL-2.
  • PATIENTS AND METHODS: A retrospective analysis was performed on all adult patients with stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at the University of Minnesota.
  • HD IL-2 was given intravenously every 8 hours at 600,000 IU/kg for a maximum of 14 doses per course.
  • RESULTS: Fifteen patients with metastatic melanoma had been treated with HD IL-2.
  • There were 4 patients exhibiting some response, with 1 complete response (CR), 1 partial response (PR), 1 mixed response (MR) and 2 stable disease (SD).
  • Average time to disease progression (TTDP) was 5.67 months.
  • Two patients had complete resolution of brain lesions after HD IL-2 therapy.
  • One of these patients experienced CR and is disease free 34 months after stopping therapy.
  • The other patient experienced MR and is currently alive with disease, but without recurrence of brain lesions.
  • CONCLUSION: We propose further evaluation of HD IL-2 in patients with brain metastases because this patient population is typically considered ineligible for HD IL-2 therapy.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. L-Lactate Dehydrogenase / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846971.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


80. Salgado OJ, Terán NA, Rosales B, Garcia RA: Subcutaneous transposition of the superficial femoral artery for arterioarterial hemodialysis: technique and results. Artif Organs; 2008 Dec;32(12):969-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the use of subcutaneous transposition of the femoral artery (STFA) for placement of both inflow and outflow needles in 14 hemodialysis (HD) adult patients with difficult access.
  • Follow-up time was 318 months during which a total of 3215 arterioarterial HD sessions were done.
  • [MeSH-minor] Adult. Aneurysm / etiology. Aneurysm, False / etiology. Constriction, Pathologic / etiology. Female. Follow-Up Studies. Hemorrhage / etiology. Humans. Infection / etiology. Male. Middle Aged. Outcome Assessment (Health Care). Thrombosis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133026.001).
  • [ISSN] 1525-1594
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Magnotti MA, Rayfield EJ: An analysis of the HumaPen Luxura HD pen: what is the role of 0.5-unit insulin dosing? J Diabetes Sci Technol; 2010 Mar 01;4(2):357-8
MedlinePlus Health Information. consumer health - Diabetes Type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of the HumaPen Luxura HD pen: what is the role of 0.5-unit insulin dosing?
  • The HumaPen Luxura HD is an insulin pen device that has the ability to deliver insulin in half-unit increments.
  • Clinical experience in treating a select group of adults with diabetes demonstrates the need for such a device.
  • [MeSH-minor] Adult. Caregivers. Child. Dose-Response Relationship, Drug. Humans. Hypoglycemia / prevention & control. Hypoglycemic Agents / administration & dosage. Hypoglycemic Agents / therapeutic use. Self Care. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Diabetes Technology Society.
  • [Cites] J Diabetes Sci Technol. 2010 Mar;4(2):353-6 [20307396.001]
  • (PMID = 20307397.001).
  • [ISSN] 1932-2968
  • [Journal-full-title] Journal of diabetes science and technology
  • [ISO-abbreviation] J Diabetes Sci Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / Insulin
  • [Other-IDs] NLM/ PMC2864172
  •  go-up   go-down


82. Langbehn DR, Hayden MR, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group: CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet; 2010 Mar 05;153B(2):397-408
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.
  • CAG-repeat length in the gene for HD is inversely correlated with age of onset (AOO).
  • We use prospective diagnostic data from the PREDICT-HD longitudinal study of CAG-expanded participants to test conditional predictions derived from two survival models of AOO of HD.
  • [MeSH-major] Huntington Disease / diagnosis. Huntington Disease / genetics. Models, Theoretical. Peptides / genetics. Peptides / metabolism
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Female. Humans. Longitudinal Studies. Male. Middle Aged. Models, Statistical. Prognosis. Prospective Studies. Trinucleotide Repeats

  • Genetic Alliance. consumer health - Huntington disease.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Am J Hum Genet. 1997 May;60(5):1202-10 [9150168.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3872-6 [9108071.001]
  • [Cites] Neurology. 1999 Oct 12;53(6):1330-2 [10522893.001]
  • [Cites] Arch Neurol. 2006 Jun;63(6):883-90 [16769871.001]
  • [Cites] J Med Genet. 2007 Jan;44(1):44-50 [17018562.001]
  • [Cites] Ann Hum Genet. 2007 May;71(Pt 3):295-301 [17181545.001]
  • [Cites] Neurology. 2007 May 15;68(20):1710-7 [17502553.001]
  • [Cites] Prog Neurobiol. 2007 Nov;83(4):228-48 [17467140.001]
  • [Cites] Hum Mol Genet. 2008 Jan 15;17(2):240-55 [17947297.001]
  • [Cites] Hum Mol Genet. 2008 Apr 15;17(8):1137-46 [18192679.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):874-80 [18096682.001]
  • [Cites] Am J Hum Genet. 2009 Mar;84(3):351-66 [19249009.001]
  • [Cites] Am J Med Genet. 2000 Dec 11;95(4):366-73 [11186892.001]
  • [Cites] Am J Hum Genet. 2001 Feb;68(2):373-85 [11225602.001]
  • [Cites] Clin Genet. 2001 Sep;60(3):198-205 [11595021.001]
  • [Cites] Medicine (Baltimore). 2002 Jul;81(4):251-9 [12169880.001]
  • [Cites] Am J Med Genet A. 2003 Jun 15;119A(3):279-82 [12784292.001]
  • [Cites] Neurosci Lett. 2003 Jul 17;345(2):93-6 [12821179.001]
  • [Cites] Am J Hum Genet. 2003 Sep;73(3):682-7 [12900792.001]
  • [Cites] Clin Genet. 2004 Apr;65(4):267-77 [15025718.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Mol Cell Probes. 1993 Jun;7(3):235-9 [8366869.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):393-7 [8401588.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):398-403 [8401589.001]
  • [Cites] Hum Mol Genet. 1993 Oct;2(10):1547-9 [8268907.001]
  • [Cites] J Med Genet. 1994 May;31(5):377-82 [8064815.001]
  • [Cites] Hum Genet. 1995 Feb;95(2):231-2 [7860073.001]
  • [Cites] Am J Hum Genet. 1995 Sep;57(3):593-602 [7668287.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] Am J Hum Genet. 1996 Jul;59(1):16-22 [8659522.001]
  • [Cites] Arch Neurol. 1996 Dec;53(12):1293-6 [8970459.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):758-62 [9647305.001]
  • (PMID = 19548255.001).
  • [ISSN] 1552-485X
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS040068; United States / NINDS NIH HHS / NS / R01 NS040068-10; United States / NCATS NIH HHS / TR / UL1 TR000442; United States / NINDS NIH HHS / NS / 5R01NS40068-09; United States / NCRR NIH HHS / RR / S10 RR023392; United States / NCATS NIH HHS / TR / UL1 TR000040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 26700-71-0 / polyglutamine
  • [Other-IDs] NLM/ NIHMS274276; NLM/ PMC3048807
  •  go-up   go-down


83. Hendricks AE, Latourelle JC, Lunetta KL, Cupples LA, Wheeler V, MacDonald ME, Gusella JF, Myers RH: Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG). Am J Med Genet A; 2009 Jul;149A(7):1375-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG).
  • Huntington disease (HD) is a dominantly transmitted neurodegenerative disorder that arises from expansion of a CAG trinucleotide repeat on chromosome 4p16.3.
  • Fathers, but not mothers, with high normal alleles are at risk of transmitting potentially penetrant HD alleles (>or=36) to offspring.
  • We estimated the conditional probability of an offspring inheriting an expanded penetrant allele given a father with a high normal allele by applying probability definitions and rules to estimates of HD incidence, paternal birth rate, frequency of de novo HD, and frequency of high normal alleles in the general population.

  • Genetic Alliance. consumer health - Huntington disease.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 2001 Apr;38(4):E12 [11283208.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):425-9 [18712713.001]
  • [Cites] Neurology. 2002 Jan 8;58(1):79-84 [11781409.001]
  • [Cites] Stat Med. 2003 Oct 30;22(20):3249-62 [14518026.001]
  • [Cites] Genet Med. 2004 Jan-Feb;6(1):61-5 [14726813.001]
  • [Cites] Am J Hum Genet. 1991 Jul;49(1):76-87 [1829582.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • [Cites] Nat Genet. 1993 Oct;5(2):168-73 [8252042.001]
  • [Cites] Nat Genet. 1993 Oct;5(2):174-9 [8252043.001]
  • [Cites] N Engl J Med. 1994 May 19;330(20):1401-6 [8159192.001]
  • [Cites] Arch Neurol. 1994 Jul;51(7):696-8 [8018043.001]
  • [Cites] Am J Hum Genet. 1995 Aug;57(2):343-50 [7668260.001]
  • [Cites] Hum Mol Genet. 1995 Oct;4(10):1911-8 [8595415.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):301-9 [9063751.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1198-211 [9545414.001]
  • [Cites] Clin Genet. 2006 Oct;70(4):283-94 [16965319.001]
  • [Cites] BMC Med Genet. 2006;7:71 [16914060.001]
  • [Cites] Mov Disord. 2007 Jan;22(1):127-30 [17115386.001]
  • [Cites] J Med Genet. 2007 Nov;44(11):695-701 [17660463.001]
  • [Cites] Mov Disord. 2008 Apr 30;23(6):879-81 [18307262.001]
  • [Cites] Mov Disord. 2008 Aug 15;23(11):1596-601 [18649400.001]
  • [Cites] Mov Disord. 2008 Sep 15;23(12):1795-6; author reply 1793 [18548610.001]
  • [Cites] Mov Disord. 2008 Sep 15;23(12):1794-5; author reply 1793 [18548612.001]
  • [Cites] Clin Genet. 2001 Sep;60(3):198-205 [11595021.001]
  • (PMID = 19507258.001).
  • [ISSN] 1552-4833
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS049206-04; United States / NINDS NIH HHS / NS / NS016367-290016; United States / NINDS NIH HHS / NS / NS016367-280014; United States / NINDS NIH HHS / NS / P50 NS016367; United States / NINDS NIH HHS / NS / R01 NS049206; United States / NINDS NIH HHS / NS / R01 NS049206-04; United States / NINDS NIH HHS / NS / P50 NS16367; United States / NCRR NIH HHS / RR / 1S10RR163736-01A1; United States / NINDS NIH HHS / NS / P50 NS016367-280014; United States / NINDS NIH HHS / NS / NS049206; United States / NINDS NIH HHS / NS / P50 NS016367-290016
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS135073; NLM/ PMC2724761
  •  go-up   go-down


84. Weber W, Siekmann R, Kis B, Kuehne D: Treatment and follow-up of 22 unruptured wide-necked intracranial aneurysms of the internal carotid artery with Onyx HD 500. AJNR Am J Neuroradiol; 2005 Sep;26(8):1909-15
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and follow-up of 22 unruptured wide-necked intracranial aneurysms of the internal carotid artery with Onyx HD 500.
  • BACKGROUND AND PURPOSE: The purpose of this study was to demonstrate endovascular treatment of wide-necked aneurysms of the internal carotid artery with the liquid embolic agent Onyx HD 500.
  • METHODS: Twenty-two wide-necked, large or giant aneurysms of the internal carotid artery (ICA) were treated in 22 patients with Onyx HD 500 (15 ophthalmic, 1 clinoid, and 6 cavernous aneurysms).
  • CONCLUSION: The endovascular treatment of wide-necked, large or giant ICA aneurysms with Onyx HD 500 is a treatment option in these selected cases.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Foreign-Body Migration / etiology. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155133.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Onyx HD 500; 0 / Polyvinyls; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


85. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahman S, Licht T, Baumert J, Straka C, Hentrich M, Salat C, Hiddemann W, Issels RD: Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology; 2006;71(1-2):32-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
  • High-dose chemotherapy consisted of ifosfamide 12 g/m(2), carboplatin 1.2 g/m(2) and etoposide 1.2 g/m(2) (HD-ICE) followed by reinfusion of PBSCs.
  • By intent-to-treat analysis the probability of 5-year progression-free survival was significantly higher for patients allocated to HD-ICE compared to patients receiving second-line chemotherapy after failure of AI-G (14 vs. 3%; p = 0.003).
  • CONCLUSION: HD-ICE is feasible and promising in patients with chemosensitive MSTS.
  • A randomized phase III trial is warranted to further define the role of HD-ICE as consolidation treatment in these patients.
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Feasibility Studies. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Prospective Studies. Salvage Therapy. Survival Rate. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344669.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


86. Huntington Study Group TREND-HD Investigators: Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol; 2008 Dec;65(12):1582-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
  • OBJECTIVE: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid, improves the motor features of Huntington disease.
  • PATIENTS: Three hundred sixteen adults with Huntington disease, enriched for a population with shorter trinucleotide (cytosine-adenine-guanine) repeat length expansions.
  • MAIN OUTCOME MEASURES: Six-month change in the Total Motor Score 4 component of the Unified Huntington's Disease Rating Scale analyzed for all research participants and those with shorter cytosine-adenine-guanine repeat length expansions (<45).
  • CONCLUSION: Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebo-controlled evaluation.
  • [MeSH-major] Eicosapentaenoic Acid / analogs & derivatives. Huntington Disease / drug therapy. Huntington Disease / physiopathology
  • [MeSH-minor] Adult. Analysis of Variance. Canada. Double-Blind Method. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neuropsychological Tests. Severity of Illness Index. Treatment Outcome. Trinucleotide Repeat Expansion / genetics. United States

  • Genetic Alliance. consumer health - Huntington disease.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Neurol. 2009 Mar;66(3):305
  • (PMID = 19064745.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00146211
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ethyl eicosapentaenoic acid; AAN7QOV9EA / Eicosapentaenoic Acid
  • [Investigator] Dorsey ER; Shoulson I; Leavitt B; Ross C; Beck CA; de Blieck EA; Greenamyre JT; Hersch SM; Kieburtz K; Marder K; McCallum C; Moskowitz C; Oakes D; Rosenblatt A; Shinaman A; Frucht S; Margolis R; Corey-Bloom J; Hersch SM; Mook L; Shannon K; Jaglin J; Sanchez-Ramos J; Wheelock V; Tempkin T; Dure LS; Guttman M; Feigin A; Shannon B; Anderson KE; Racette BA; Higgins D; Agarwal P; Seeberger L; Montellano S; Kostyk S; Seward A; Nance M; Raymond LA; Decolongon J; Suchowersky O; Beglinger L; Paulson H; Como P; Barbano R; Zimmerman C; Wojcieszek J; Jog M; Horn C; Dubinsky RM; Martin W; Wieler M; LeDoux MS; Harrison MB; Morgan JC; Dill B; Singer C; Quesada M; Kartha N; Wernette K; Frank S; Fernandez H; Jennings D; Kelsey T; Hunter C; Beck C; Bourgeois K; de Blieck EA; Deuel L; McCallum C; McMullen N; Oakes D; Ross V; Rumfola L; Watts A; Weaver C; Winebrenner T; Tariot PN
  •  go-up   go-down


87. Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, Frati L, Gómez-Tortosa E, García CA, Suchowersky O, Klimek ML, Trent RJ, McCusker E, Novelletto A, Frontali M, Paulsen JS, Jones R, Ashizawa T, Lazzarini A, Wheeler VC, Prakash R, Xu G, Djoussé L, Mysore JS, Gillis T, Hakky M, Cupples LA, Saint-Hilaire MH, Cha JH, Hersch SM, Penney JB, Harrison MB, Perlman SL, Zanko A, Abramson RK, Lechich AJ, Duckett A, Marder K, Conneally PM, Gusella JF, MacDonald ME, Myers RH: Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet; 2006 Aug 17;7:71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study.
  • BACKGROUND: Age at onset of Huntington's disease (HD) is correlated with the size of the abnormal CAG repeat expansion in the HD gene; however, several studies have indicated that other genetic factors also contribute to the variability in HD age at onset.
  • To identify modifier genes, we recently reported a whole-genome scan in a sample of 629 affected sibling pairs from 295 pedigrees, in which six genomic regions provided suggestive evidence for quantitative trait loci (QTL), modifying age at onset in HD.
  • CONCLUSION: In this replication study, linkage for modifier of age at onset in HD was confirmed at 6q23-24.
  • The demonstration of statistically significant linkage to a potential modifier locus opens the path to location cloning of a gene capable of altering HD pathogenesis, which could provide a validated target for therapeutic development in the human patient.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4518-23 [15576372.001]
  • [Cites] J Neurosci Res. 2000 Oct 15;62(2):257-72 [11020218.001]
  • [Cites] Am J Med Genet. 2001 Jul 8;105(5):399-403 [11449389.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] Am J Med Genet A. 2003 Jun 15;119A(3):279-82 [12784292.001]
  • [Cites] Am J Hum Genet. 2003 Sep;73(3):682-7 [12900792.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(2):273-9 [14725621.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 Feb 15;125B(1):92-8 [14755452.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503 [14993615.001]
  • [Cites] Am J Hum Genet. 1984 May;36(3):506-26 [6233902.001]
  • [Cites] Arch Neurol. 1987 Jan;44(1):109-13 [2948483.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):241-7 [7581446.001]
  • [Cites] Neuropharmacology. 1996;35(12):1649-60 [9076744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3872-6 [9108071.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1198-211 [9545414.001]
  • [Cites] Hum Mol Genet. 1998 Sep;7(9):1463-74 [9700202.001]
  • [Cites] Am J Hum Genet. 1998 Sep;63(3):861-9 [9718341.001]
  • [Cites] Neurology. 1999 Oct 12;53(6):1330-2 [10522893.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D447-53 [15608235.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):387-92 [8401587.001]
  • (PMID = 16914060.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50NS016367; United States / NINDS NIH HHS / NS / NS16375; United States / NINDS NIH HHS / NS / P50 NS016367; United States / NINDS NIH HHS / NS / R01 NS032765; United States / NCRR NIH HHS / RR / 1S10RR163736-01A1; United States / NINDS NIH HHS / NS / NS32765; United States / NINDS NIH HHS / NS / P01 NS016375
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC1586197
  •  go-up   go-down


88. Kakinoki M, Sawada O, Sawada T, Kawamura H, Ohji M: Comparison of macular thickness between Cirrus HD-OCT and Stratus OCT. Ophthalmic Surg Lasers Imaging; 2009 Mar-Apr;40(2):135-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of macular thickness between Cirrus HD-OCT and Stratus OCT.
  • [MeSH-minor] Adult. Female. Fourier Analysis. Humans. Interferometry. Male. Reference Values. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19320302.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Shippy TD, Yeager SJ, Denell RE: The Tribolium spineless ortholog specifies both larval and adult antennal identity. Dev Genes Evol; 2009 Jan;219(1):45-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Tribolium spineless ortholog specifies both larval and adult antennal identity.
  • Moreover, this knowledge applies mostly to adult structures, since Drosophila lacks external larval appendages.
  • In contrast to Drosophila, the red flour beetle, Tribolium castaneum, has both larval and adult antennae, which are very different from one another in morphology.
  • Here, we report that the Tribolium ortholog of spineless (Tc-ss) is required in both the larval and adult antennae.
  • Thus, the function of ss is conserved between Drosophila and Tribolium with respect to adult antennal specification and also between Tribolium larval and adult antennal development.
  • These results represent a first step in characterizing larval and adult antennal patterning in Tribolium, which should provide important insights into the evolution of insect antennal development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genetics. 1999 Sep;153(1):333-8 [10471716.001]
  • [Cites] Dev Genes Evol. 2008 Apr;218(3-4):127-39 [18392875.001]
  • [Cites] Development. 2000 Jan;127(2):209-16 [10603339.001]
  • [Cites] Evol Dev. 1999 Jul-Aug;1(1):11-5 [11324015.001]
  • [Cites] J Histochem Cytochem. 2001 Sep;49(9):1177-82 [11511686.001]
  • [Cites] Curr Biol. 2002 Feb 5;12(3):R85-6 [11839285.001]
  • [Cites] Development. 2002 Apr;129(8):1967-74 [11934862.001]
  • [Cites] Development. 2003 Mar;130(6):1171-80 [12571108.001]
  • [Cites] Dev Biol. 2003 Aug 15;260(2):465-83 [12921746.001]
  • [Cites] Genetics. 1982 Dec;102(4):737-49 [6821249.001]
  • [Cites] Development. 1995 Jul;121(7):2117-25 [7635057.001]
  • [Cites] Development. 1995 Nov;121(11):3663-73 [8582279.001]
  • [Cites] Genes Dev. 1998 Feb 1;12(3):435-46 [9450936.001]
  • [Cites] Nature. 1998 Apr 16;392(6677):723-6 [9565034.001]
  • [Cites] Genes Dev. 1998 May 1;12(9):1290-303 [9573046.001]
  • [Cites] Development. 1999 Sep;126(17):3937-45 [10433921.001]
  • [Cites] Dev Genes Evol. 2004 Nov;214(11):575-8 [15365833.001]
  • [Cites] Genetics. 2005 Jun;170(2):741-7 [15834150.001]
  • [Cites] Dev Biol. 2007 Feb 15;302(2):412-26 [17084833.001]
  • [Cites] Insect Mol Biol. 2007 Jun;16(3):265-75 [17316329.001]
  • [Cites] Nature. 2008 Apr 24;452(7190):949-55 [18362917.001]
  • (PMID = 19030877.001).
  • [ISSN] 1432-041X
  • [Journal-full-title] Development genes and evolution
  • [ISO-abbreviation] Dev. Genes Evol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD029594-15; United States / NICHD NIH HHS / HD / R01 HD029594-08; United States / NICHD NIH HHS / HD / HD029594-09; United States / NICHD NIH HHS / HD / R01HD029594; United States / NICHD NIH HHS / HD / HD029594-10; United States / NICHD NIH HHS / HD / R01 HD029594-16; United States / NICHD NIH HHS / HD / R01 HD029594-09; United States / NICHD NIH HHS / HD / R01 HD029594; United States / NICHD NIH HHS / HD / HD029594-08; United States / Howard Hughes Medical Institute / / ; United States / NICHD NIH HHS / HD / R01 HD029594-10; United States / NICHD NIH HHS / HD / R01 HD029594-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Insect Proteins; 0 / Receptors, Aryl Hydrocarbon
  • [Other-IDs] NLM/ NIHMS75424; NLM/ PMC2605184
  •  go-up   go-down


90. Lichtenwalner RJ, Parent JM: Adult neurogenesis and the ischemic forebrain. J Cereb Blood Flow Metab; 2006 Jan;26(1):1-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neurogenesis and the ischemic forebrain.
  • The recent identification of endogenous neural stem cells and persistent neuronal production in the adult brain suggests a previously unrecognized capacity for self-repair after brain injury.
  • Neurogenesis not only continues in discrete regions of the adult mammalian brain, but new evidence also suggests that neural progenitors form new neurons that integrate into existing circuitry after certain forms of brain injury in the adult.
  • Experimental stroke in adult rodents and primates increases neurogenesis in the persistent forebrain subventricular and hippocampal dentate gyrus germinative zones.
  • This review summarizes the current understanding of adult neurogenesis and its regulation in vivo, and describes evidence for stroke-induced neurogenesis and neuronal replacement in the adult.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15959458.001).
  • [ISSN] 0271-678X
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD44775; United States / NINDS NIH HHS / NS / NS42143
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 209
  •  go-up   go-down


91. Manjunath V, Taha M, Fujimoto JG, Duker JS: Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol; 2010 Sep;150(3):325-329.e1
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography.
  • METHODS: Thirty-four eyes (34 subjects), with no retinal or choroidal disease, underwent high-definition raster scanning using SD-OCT with frame enhancement software.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • [Cites] Exp Eye Res. 2004 Jun;78(6):1117-25 [15109918.001]
  • [Cites] Opt Lett. 2004 Sep 15;29(18):2139-41 [15460882.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1178-81 [1957169.001]
  • [Cites] Br J Ophthalmol. 2005 Feb;89(2):207-12 [15665354.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1165-8 [16765704.001]
  • [Cites] J Biomed Opt. 2007 Jul-Aug;12(4):041211 [17867800.001]
  • [Cites] Am J Ophthalmol. 2008 Oct;146(4):496-500 [18639219.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Nov;49(11):5103-10 [18658089.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Jan;50(1):405-13 [18676629.001]
  • [Cites] Am J Ophthalmol. 2009 Apr;147(4):644-52 [19152869.001]
  • [Cites] Am J Ophthalmol. 2009 May;147(5):811-5 [19232559.001]
  • [Cites] Am J Ophthalmol. 2009 May;147(5):801-10 [19232561.001]
  • [Cites] Am J Ophthalmol. 2009 Sep;148(3):445-50 [19541286.001]
  • [Cites] Retina. 2009 Nov-Dec;29(10):1469-73 [19898183.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2173-6 [19892874.001]
  • (PMID = 20591395.001).
  • [ISSN] 1879-1891
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / EY011289-24; United States / NEI NIH HHS / EY / R01-EY013516-07; United States / NEI NIH HHS / EY / EY011289-26; United States / NEI NIH HHS / EY / R01-EY11289-24; United States / NEI NIH HHS / EY / R01 EY013178; United States / NEI NIH HHS / EY / R01 EY011289-24; United States / NEI NIH HHS / EY / R01-EY13178-10; United States / NEI NIH HHS / EY / R01 EY011289; United States / NEI NIH HHS / EY / R01 EY011289-26; United States / NEI NIH HHS / EY / R01 EY013516
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS202437; NLM/ PMC2926223
  •  go-up   go-down


92. Halpern CT, Waller MW, Spriggs A, Hallfors DD: Adolescent predictors of emerging adult sexual patterns. J Adolesc Health; 2006 Dec;39(6):926.e1-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescent predictors of emerging adult sexual patterns.
  • PURPOSE: This study estimates the percentages of young adults who fall into three groups based on the context of sexual transition:.
  • The second purpose is to determine adolescent biopsychosocial factors that predict membership in these adult groups.
  • Adolescent indicators reflecting sociodemographic, biosocial, experiential, and contextual factors were used to predict young adult sexual status using multinomial logistic regression models.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Logistic Models. Longitudinal Studies. Male. North Carolina / epidemiology. Parent-Child Relations. Risk Assessment. Sex Distribution. Sexual Abstinence / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116527.001).
  • [ISSN] 1879-1972
  • [Journal-full-title] The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • [ISO-abbreviation] J Adolesc Health
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / P01-HD31921; United States / NIDA NIH HHS / DA / R01-DA14496
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Nijland MJ, Ford SP, Nathanielsz PW: Prenatal origins of adult disease. Curr Opin Obstet Gynecol; 2008 Apr;20(2):132-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal origins of adult disease.
  • PURPOSE OF REVIEW: Human epidemiological and animal studies show that many chronic adult conditions have their antecedents in compromised fetal and early postnatal development.
  • A better understanding is required of gene-environment interactions leading to adult disease.
  • RECENT FINDINGS: During development, there are critical periods of vulnerability to suboptimal conditions when programming may permanently modify disease susceptibility.
  • SUMMARY: Developmental programming shows that epigenetic factors play major roles in development of phenotype and predisposition to disease in later life.

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18388812.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD021350; United States / NICHD NIH HHS / HD / HD 21350; United States / NCRR NIH HHS / RR / P20 RR16474-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 124
  •  go-up   go-down


94. Roper K, McDermott K, Cooley ME, Daley K, Fawcett J: Health-related quality of life in adults with Hodgkin's disease: the state of the science. Cancer Nurs; 2009 Nov-Dec;32(6):E1-17; quiz E18-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in adults with Hodgkin's disease: the state of the science.
  • Hodgkin's disease (HD) affects younger and older adults and can disrupt developmental tasks and cause multiple medical sequelae.
  • This article is an integrative review of empirical studies of HRQOL in HD survivors.
  • Commonly reported physical consequences of HD include fatigue, anticipatory nausea and vomiting, and cognitive problems that lasted several years after treatment completion, as well as long-term life-threatening adverse effects including secondary cancers and cardiovascular and respiratory complications.
  • Development of appropriate theory-guided interventions to improve the HRQOL for HD survivors can be achieved through more rigorous study designs and standardization of HRQOL measurements.
  • [MeSH-major] Education, Nursing, Graduate / standards. Hodgkin Disease / psychology. Oncology Nursing / education. Quality of Life / psychology
  • [MeSH-minor] Adaptation, Psychological. Adult. Humans. Survivors / psychology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816166.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 U56 CA11863502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


95. Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B: Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol; 2005 Jul;84(7):462-73
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Between 1990 and 2001, 68 patients with advanced Hodgkin's disease (HD) and 86 patients classified as low-/intermediate-grade B non-Hodgkin's lymphoma (NHL) were reported to the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Following autologous stem cell transplantation (SCT) for HD, overall survival was 56% [95% confidence interval (CI): 40-72%] with a disease-/progression-free survival of 49%, reaching a plateau at 5 years.
  • Using multivariate Cox regression analysis BEAM conditioning (carmustine, cytarabine, etoposide and melphalan) was predictive for favourable outcome, better disease-/progression-free survival and a significantly lower risk for relapse.
  • Overall survival for NHL patients was 45% (95% CI: 26-64%) with a disease-/progression-free survival of 26% at 7 years.
  • In the multivariate Cox regression analysis stage of disease at time of SCT was the most powerful parameter for overall survival, disease-/progression-free survival and relapse.
  • Mantle cell lymphoma, greater than or equal to three lines of previous therapy, and a conditioning regimen other than BEAM were also predictive for death.
  • Because of the high risk of relapse/progression in both disease categories and the additional high rate of second malignancies in HD patients, allogeneic stem cells should be considered a valuable alternative for selected patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Transplantation, Autologous
  • [MeSH-minor] Adolescent. Adult. Austria. Child. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Recurrence. Registries. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726362.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Bozzoli C, Deaton A, Quintana-Domeque C: Adult height and childhood disease. Demography; 2009 Nov;46(4):647-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult height and childhood disease.
  • In consequence, adult height has recently become a focus in understanding the relationship between health and wealth.
  • We investigate the childhood determinants of population adult height, focusing on the respective roles of income and of disease.
  • Across a range of European countries and the United States, we find a strong inverse relationship between postneonatal (ages 1 month to 1 year) mortality, interpreted as a measure of the disease and nutritional burden in childhood, and the mean height of those children as adults.
  • Consistent with these findings, we develop a model of selection and stunting in which the early-life burden of undernutrition and disease not only is responsible for mortality in childhood but also leaves a residue of long-term health risks for survivors, risks that express themselves in adult height and in late-life disease.

  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Soc Sci Med. 1998 Nov;47(9):1231-46 [9783866.001]
  • [Cites] Ann Hum Biol. 1995 Jan-Feb;22(1):57-67 [7762976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):498-503 [16387863.001]
  • [Cites] J R Soc Med. 2006 May;99(5):250-7 [16672759.001]
  • [Cites] Econ Hum Biol. 2007 Jul;5(2):340-9 [17412655.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13232-7 [17686991.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13219-24 [17686992.001]
  • [Cites] J Econ Perspect. 2008 Winter;22(1):129-152 [19771661.001]
  • [Cites] Monogr Ser World Health Organ. 1968;57:3-329 [4976616.001]
  • [Cites] Am J Epidemiol. 2000 Jun 1;151(11):1112-20 [10873136.001]
  • [Cites] J Epidemiol Community Health. 2000 Sep;54(9):660-6 [10942444.001]
  • [Cites] Proc Nutr Soc. 2000 May;59(2):317-24 [10946801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2934-9 [11226344.001]
  • [Cites] Popul Index. 1992 Summer;58(2):186-212 [12285320.001]
  • [Cites] Demography. 2002 Feb;39(1):119-37 [11852833.001]
  • [Cites] J Biosoc Sci. 2003 Apr;35(2):263-85 [12664962.001]
  • [Cites] Science. 2004 Sep 17;305(5691):1736-9 [15375259.001]
  • [Cites] Acta Med Scand Suppl. 1984;679:1-56 [6585126.001]
  • [Cites] J Epidemiol Community Health. 1995 Feb;49(1):5-9 [7707006.001]
  • [Cites] Prenat Diagn. 1999 Sep;19(9):808-12 [10521836.001]
  • (PMID = 20084823.001).
  • [ISSN] 0070-3370
  • [Journal-full-title] Demography
  • [ISO-abbreviation] Demography
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD047879; United States / NIA NIH HHS / AG / R01 AG020275-01; United States / NIA NIH HHS / AG / R01 AG020275; United States / NIA NIH HHS / AG / R01 AG20275-01; United States / NIA NIH HHS / AG / AG020275-01; United States / NIA NIH HHS / AG / P01 AG005842; United States / NIA NIH HHS / AG / P01 AG005842-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS84610; NLM/ PMC2809930
  •  go-up   go-down


97. Beran MJ, Taglialatela LA, Flemming TM, James FM, Washburn DA: Nonverbal estimation during numerosity judgements by adult humans. Q J Exp Psychol (Hove); 2006 Dec;59(12):2065-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonverbal estimation during numerosity judgements by adult humans.
  • These data indicate a mechanism for the approximate representation of numerosity in adult humans that might be shared with nonhuman animals.
  • [MeSH-minor] Adult. Attention. Cognition. Female. Humans. Male. Mathematics. Space Perception

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095488.001).
  • [ISSN] 1747-0218
  • [Journal-full-title] Quarterly journal of experimental psychology (2006)
  • [ISO-abbreviation] Q J Exp Psychol (Hove)
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-38051
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


98. Emsley JG, Mitchell BD, Kempermann G, Macklis JD: Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog Neurobiol; 2005 Apr;75(5):321-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells.
  • Recent work in neuroscience has shown that the adult central nervous system contains neural progenitors, precursors, and stem cells that are capable of generating new neurons, astrocytes, and oligodendrocytes.
  • While challenging previous dogma that no new neurons are born in the adult mammalian CNS, these findings bring with them future possibilities for the development of novel neural repair strategies.
  • The purpose of this review is to present current knowledge about constitutively occurring adult mammalian neurogenesis, to highlight the critical differences between "neurogenic" and "non-neurogenic" regions in the adult brain, and to describe the cardinal features of two well-described neurogenic regions-the subventricular zone/olfactory bulb system, and the dentate gyrus of the hippocampus.
  • The possibility of repairing neural circuitry by manipulating neurogenesis is an intriguing one, and, therefore, we also review recent efforts to understand the conditions under which neurogenesis can be induced in non-neurogenic regions of the adult CNS.
  • We conclude this review with a discussion of what the function might be of newly generated neurons in the adult brain and provide a summary of current thinking about the consequences of disturbed adult neurogenesis and the reaction of neurogenic regions to disease.
  • [MeSH-minor] Adult. Animals. Cell Differentiation / physiology. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913880.001).
  • [ISSN] 0301-0082
  • [Journal-full-title] Progress in neurobiology
  • [ISO-abbreviation] Prog. Neurobiol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD18655; United States / NINDS NIH HHS / NS / NS41590; United States / NINDS NIH HHS / NS / NS45523; United States / NINDS NIH HHS / NS / NS49553
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 206
  •  go-up   go-down


99. Lem KE, Brinster LR, Tjurmina O, Lizak M, Lal S, Centeno JA, Liu PC, Godwin SC, Kaler SG: Safety of intracerebroventricular copper histidine in adult rats. Mol Genet Metab; 2007 May;91(1):30-6
Hazardous Substances Data Bank. (L)-HISTIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of intracerebroventricular copper histidine in adult rats.
  • Classical Menkes disease is an X-linked recessive neurodegenerative disorder caused by mutations in a P-type ATPase (ATP7A) that normally delivers copper to the developing central nervous system.
  • To begin to evaluate an aggressive but potentially useful new strategy for metabolic improvement of this disorder, we studied the acute and chronic effects of CuHis administered by intracerebroventricular (ICV) injection in healthy adult rats.
  • Based on estimates of the brain copper deficit in Menkes disease patients, CuHis doses 10-fold lower than the MTD found in this study may restore proper brain copper concentration.
  • Our results suggest that ICV CuHis administration have potential as a novel treatment approach in Menkes disease infants with severe mutations.
  • Future trials of direct CNS copper administration in mouse models of Menkes disease will be informative.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1987 Nov 26;317(22):1415-6 [3683474.001]
  • [Cites] Neuroimage. 2004 Jul;22(3):1046-59 [15219577.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):14-9 [8490646.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):20-5 [8490647.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):7-13 [8490659.001]
  • [Cites] Exp Neurol. 1994 May;127(1):23-36 [8200435.001]
  • [Cites] Adv Pediatr. 1994;41:263-304 [7992686.001]
  • [Cites] Nature. 1995 Apr 13;374(6523):643-6 [7715704.001]
  • [Cites] Ann Neurol. 1995 Dec;38(6):921-8 [8526465.001]
  • [Cites] Brain Res. 1995 Oct 9;695(1):53-8 [8574647.001]
  • [Cites] Nat Genet. 1996 May;13(1):21-2 [8673098.001]
  • [Cites] Biochem Mol Med. 1996 Feb;57(1):37-46 [8812725.001]
  • [Cites] J Neurochem. 1999 Jan;72(1):422-9 [9886096.001]
  • [Cites] Pediatrics. 2005 Feb;115(2):286-94 [15687434.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):640-8 [15723400.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Apr 4;134(2):323-32 [15836927.001]
  • [Cites] Mol Genet Metab. 2005 Aug;85(4):291-300 [15923132.001]
  • [Cites] Neuroscience. 2006;139(3):947-64 [16549268.001]
  • [Cites] Brain Res. 2000 Apr 28;863(1-2):241-4 [10773212.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25057-60 [10816601.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7614-21 [12370308.001]
  • [Cites] J Med Genet. 2003 Apr;40(4):290-5 [12676902.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):978-87 [15122680.001]
  • [Cites] J Biol Chem. 1988 Jan 15;263(2):799-805 [3335527.001]
  • (PMID = 17336116.001).
  • [ISSN] 1096-7192
  • [Journal-full-title] Molecular genetics and metabolism
  • [ISO-abbreviation] Mol. Genet. Metab.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD008768-02
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 4QD397987E / Histidine; 77280-83-2 / copper histidine
  • [Other-IDs] NLM/ NIHMS22366; NLM/ PMC2570033
  •  go-up   go-down


100. Magavi SS, Mitchell BD, Szentirmai O, Carter BS, Macklis JD: Adult-born and preexisting olfactory granule neurons undergo distinct experience-dependent modifications of their olfactory responses in vivo. J Neurosci; 2005 Nov 16;25(46):10729-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-born and preexisting olfactory granule neurons undergo distinct experience-dependent modifications of their olfactory responses in vivo.
  • Neurogenesis continues throughout adulthood in the mammalian olfactory bulb and hippocampal dentate gyrus, suggesting the hypothesis that recently generated, adult-born neurons contribute to neural plasticity and learning.
  • To explore this hypothesis, we examined whether olfactory experience modifies the responses of adult-born neurons to odorants, using immediate early genes (IEGs) to assay the response of olfactory granule neurons.
  • We find that, shortly after they differentiate and synaptically integrate, the population of adult-born olfactory granule neurons has a greater population IEG response to novel odors than mature, preexisting neurons.
  • Familiarizing mice with test odors increases the response of the recently incorporated adult-born neuron population to the test odors, and this increased responsiveness is long lasting, demonstrating that the response of the adult-born neuron population is altered by experience.
  • In contrast, familiarizing mice with test odors decreases the IEG response of developmentally generated neurons, suggesting that recently generated adult-born neurons play a distinct role in olfactory processing.
  • The increased IEG response is stimulus specific; familiarizing mice with a set of different, "distractor" odors does not increase the adult-born neuron population response to the test odors.
  • Odor familiarization does not influence the survival of adult-born neurons, indicating that the changes in the population response of adult-born neurons are not attributable to increased survival of odor-stimulated neurons.
  • These results demonstrate that recently generated adult-born olfactory granule neurons and older, preexisting granule neurons undergo contrasting experience-dependent modifications in vivo and support the hypothesis that adult-born neurons are involved in olfactory learning.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291946.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD18655; United States / NINDS NIH HHS / NS / NS41590; United States / NINDS NIH HHS / NS / NS45523; United States / NINDS NIH HHS / NS / NS49553
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement